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ABSTRACT 
 
 
EFFECT OF THE FLAVONOID QUERCETIN ON 
ADIPOCYTES 
 
SEPTEMBER 2011 
 
JENNIFER C SWICK, B.S., UNIVERSITY OF MASSACHUSETTS, AMHERST 
M.S. UNIVERSITY OF MASSACHUSETTS, AMHERST 
 
DIRECTED BY: PROFESSOR YOUNG-CHEUL KIM 
 
 Obesity is an urgent global public health concern as prevalence rates continue 
to increase, especially among children. Obesity is defined at the cellular level as an 
increase in adipocyte number (hyperplasia) and size (hypertrophy). Both lead to the 
dysfunction of adipose tissue, which has been identified as the link between obesity 
and chronic disease. Bioactive compounds, naturally occurring in fruits and vegetables, 
hold enormous potential in regulating adipocyte biology. Quercetin, the most 
commonly consumed dietary flavonoid, is a strong potential anti-obesity agent that has 
been implicated as an AMP-activated protein kinase (AMPK) activator and shown to 
ameliorate symptoms of metabolic syndrome in vivo. Here we investigated quercetin’s 
effect on (1) adipogenesis, the process of increasing adipocyte number, and (2) 
metabolism of mature adipocytes. In 3T3-L1 preadipocytes, quercetin dose-
dependently inhibited adipogenesis, as evidenced by decreased lipid accumulation and 
expression of adipogenic markers such as  peroxisome proliferator-activated receptor 
(PPAR) γ, CCAAT/ enhancer binding protein (C/EBP) α, adipocyte fatty acid binding 
protein 2 (aP2), and acetyl-CoA carboxylase (ACC) on mRNA and protein levels. This 
inhibitory effect was limited to the early stages of adipogenesis (0-36 hours), and 
vi 
 
quercetin treatment altered the normal expression pattern of cell cycle related genes 
Cyclin A and p27, indicating quercetin may inhibit adipogenesis through cell cycle 
events. We next investigated quercetin’s ability to activate AMPK and the metabolic 
pathways related to AMPK activation: lipolysis and β-oxidation. Quercetin increased 
phosphorylation of AMPK and its downstream target ACC. Further, quercetin 
treatment (100μM) increased free fatty acid content in the media through an AMPK-
dependent mechanism. Quercetin up-regulated mRNA expression of uncoupling 
proteins 3 (UCP3) and peroxisome proliferator-activated receptor-gamma co-activator 
1 alpha (PGC-1α), indicating that quercetin may induce mitochondrial oxidative 
pathways, also through an AMPK-dependent pathway. These findings suggest (1) 
quercetin inhibits adipogenesis through the regulation of early cell cycle events 
required for adipogenic differentiation, and (2) quercetin’s activation of AMPK 
induces lipolytic and oxidative pathways. Taken together, quercetin could be further 
developed as an anti-obesity agent because of its potential to inhibit both hyperplasia 
and hypertrophy in vitro.  
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CHAPTER 1 
BACKGROUND 
 
1.1 Overview 
 
 The increasing prevalence of obesity is a pressing concern for health officials 
worldwide because of its link to the development of type 2 diabetes, cardiovascular 
disease, and cancer. In the United States alone, with nearly 2/3 of adults and 17% of 
children overweight and obese, it is estimated that $147 billion is spent annually on 
obesity-related health care [1].  In the obese state, adipose tissue expands to 
accommodate excess energy intake through an increase in the number (hyperplasia) and 
size (hypertrophy) of adipocytes. Hyperplasia leads to the irreversible expansion of 
adipose tissue in unwanted depots, specifically the visceral cavity [2]. Hypertrophy 
leads to the dysfunction of adipocytes, as they become insulin resistant and recruit 
macrophages to the tissue for their own destruction [3]. Together, these events lead to 
the development of metabolic syndrome. Therefore targeting adipocyte biology, both 
hyperplasia and hypertrophy, and identifying potential factors that regulate these 
processes are of great importance in the prevention and treatment of obesity. 
 In recent years, researchers have turned to the potential of dietary bioactive 
compounds to prevent this adipocyte dysfunction and therefore help combat the rising 
obesity epidemic and reduce health care costs [4, 5]. Quercetin, the most commonly 
consumed dietary flavonoid, has been shown to ameliorate symptoms of metabolic 
syndrome in in vivo animal studies [6-10], however the exact effect of quercetin on 
adipose tissue  was not explored. 
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 Research has shown that quercetin inhibits adipogenesis in both human and 
mice cell models [11-13], and induces lipolysis [14, 15] in mature mice adipocytes; 
however the underlying mechanisms are unknown. Interestingly, quercetin has recently 
been implicated as an AMP-activated protein kinase (AMPK) activator [13]. AMPK is 
the major metabolic regulator of the cell, and a major target for obesity-related 
conditions because of its ability to induce fatty acid oxidation [16]. However, 
quercetin’s ability to alter the metabolic state of mature adipocytes has not been 
explored. Therefore, our focus was to investigate (1) mechanisms of quercetin’s anti-
adipogenic effect, and (2) metabolic effects of quercetin in mature adipocytes through 
AMPK activation. These findings will largely improve our understanding of quercetin’s 
ability to ameliorate hyperplasia and hypertrophy, and thus inform its development as 
an anti-obesity agent.  
 
1.2 The Extent of the Problem of Obesity 
 
  Obesity has become one of the most urgent concerns of health care officials 
over the past two decades, as dramatic increases in prevalence rates have been seen not 
only in the United States but worldwide. In the U.S. alone, with nearly 2/3 of adults and 
17% of children overweight or obese, it is estimated that $147 billion is spent annually 
on obesity-related health care [1]. The World Health Organization outlines the severity 
of the problem with the following: (1) worldwide obesity has more than doubled since 
1980, (2) overweight and obesity are the 5th leading cause of death globally, (3) in 2008 
more than 10% of the population was obese, (3) in 2010 nearly 43 million children 
3 
under the age of five were overweight, and (4) obesity accounts for the incidence of 
44% of diabetes, 23% of ischemic attacks, and up to 41% of certain cancers [17]. This 
places an enormous burden on health care systems and impacts health care costs 
worldwide.  
 Obesity has been linked to all of the following: coronary heart disease, type 2 
diabetes, cancer (specifically breast and colon), hypertension, dyslipidemia, stroke, 
liver and gallbladder disease, sleep apnea, osteoarthritis, and gynecological 
complications [18]. In an effort to classify the most common conditions related to 
obesity, the term “metabolic syndrome” has been used to include the development of 
hypertension, dyslipidemia, hyperglycemia, and insulin resistance. This term was 
coined because of the surprising combination of conditions seen repeatedly in 
overweight and obese patients. Currently 8.3% of the US population is affected by 
diabetes [19], 12% by cardiovascular disease [20], and 34% of adults are classified as 
having metabolic syndrome [21]. If no action is taken, the prevalence of metabolic 
syndrome will likely only increase in the population, as childhood obesity has tripled 
over the last 25 years, and continues to grow [22]. 
 At the cellular level, adipose tissue expands its capacity to store lipid by 
increasing adipocyte size (hypertrophy) and number (hyperplasia).  Hyperplasia leads 
to the expansion of adipose tissue in unwanted depots, specifically the visceral cavity, 
through the process of adipogenesis. Adipogenesis occurs in two stages: (1) the 
commitment of precursor mesenchymal stem cells to preadipocytes, and (2) the 
differentiation of preadipocytes to mature adipocytes [3]. Because adipocytes are 
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particularly resistant to apoptosis, it has been suggested that hyperplasia may be 
associated with less reversibility of metabolic consequences from obesity [23, 24]. 
 Hypertrophy of adipocytes directly leads to their dysfunction.  The 
accumulation of excess lipid leads to the malfunction of the cytosolic organelles 
resulting in insulin resistance. Eventually macrophages are recruited to the tissue, 
which creates systemic low-grade inflammation. This adipose tissue dysfunction has 
been identified as the major link between obesity and metabolic syndrome [3]. 
Therefore there are two ways to target the development of metabolic syndrome on a 
cellular level; (1) targeting adipogenesis, and (2) targeting adipocyte metabolism to 
prevent excess lipid accumulation and dysfunction. Developing prevention and 
treatment methods that make use of both strategies is vital to obesity-related research 
and would impact the financial burden facing health care systems.  
 
1.3 The Role of Adipose Tissue in the Development of Obesity 
 
1.3.1. Adipogenesis 
 The regulation of adipogenesis plays a critical part in the development of 
obesity. During childhood and adolescence, adipocyte number increases based on 
genetic and environmental factors. However, once adulthood is reached, adipocyte 
number remains relatively constant [2], even though the tissue is still capable of 
recruiting new adipocytes. Studies have shown hypertrophy precedes hyperplasia in 
adults during excess energy intake and hyperplasia is only stimulated is under sustained 
energy imbalance, such as during the development of obesity [23, 25]. Further, weight 
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loss results in a reduction in adipocyte volume but not necessarily adipocyte number [2]. 
Adipocytes are extremely resistant to apoptosis; therefore adipose tissue that has been 
expanded by hyperplasia it will be maintained, making it harder for an individual to 
sustain weight loss and worsening the prognosis for treatment [26, 27]. Targeting 
hyperplasia is thus crucial for preventing the progression of childhood and adult obesity.   
 The development of new adipocytes through the adipogenic process, occurs in 
two phases: the proliferation of preadipocytes from stromal vascular cells, and the 
terminal differentiation of preadipocytes to lipid-laden mature adipocytes.  This 
transition is tightly regulated by cell cycle events and the induction of adipogenic 
factors.  
Nearly all the progress made in understanding the regulation of adipogenesis at 
the molecular level has come from in vitro studies. Researchers have found that 
behavior of cell line models for adipogenesis, whether from mouse or human, can vary 
significantly based on depot origin, in vivo imprinting, and pluripotency stage [28]. As 
previously discussed, in vivo adipogenesis proceeds in two stages; therefore, cell 
models may reflect one or the other depending on their source of origin. 3T3-L1 murine 
preadipocytes are pre-committed to terminally differentiate into adipocytes, in response 
to hormonal stimulation. This cell line has been the most widely used cell model for 
studying adipogenic program. The 3T3-L1 cell line was derived from disaggregated 
Swiss 3T3 mouse embryos [29] and consists of unipotent preadipocytes, that have been 
shown to require mitotic clonal expansion (MCE) for terminal differentiation [30, 31] 
although it is still debated [32]. The research done in this model system thus reflects 
what might occur in vivo to pre-committed preadipocytes. Other cells lines commonly 
6 
used are 10T1/2 mesenchymal stem cells, and various human vascular stem cells 
isolated from individual patients.   
 In the 3T3-L1 cell line model, post-confluent, growth arrested preadipocytes 
can be induced to differentiate by an adipogenic cocktail consisting of methylisobutyl-
xanthine (MIX), dexamethasone (DEX), and insulin (MDI).  DEX and MIX stimulate 
glucocorticoid receptor and cAMP signaling, respectively, causing the initial up-
regulation of CCAAT/enhancer binding protein (C/EBP) δ and C/EBPβ. Cells at this 
time enter into mitotic clonal expansion (MCE), a period of replication, for roughly 48 
hours. 12-18 hours after MDI stimulation, C/EBPβ is dually phosphorylated and 
translocated into the nucleus where it binds to the DNA to help elicit PPARγ and 
CEBPα expression [33]. PPARγ and C/EBPα are the major adipogenic transcription 
factors for terminal differentiation that bring about a cascade of changes in gene 
expression and increased lipid synthesis [34].  In addition to measuring PPARγ and 
C/EBPα as indicators of adipogenesis, lipid accumulation and lipogenic genes, such as 
fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC) and adipocyte fatty acid 
binding protein (aP2), are used to determine the degree of differentiation and 
lipogenesis.  
 In vivo studies have clearly shown that cell cycle regulation is necessary for 
control of hyperplasia.  The loss of cyclin-dependent kinase inhibitors in p27 and p21 
knockout mice resulted in increased proliferation and recruitment of preadipocytes [35].  
Therefore, targeting the molecular interplay between cell cycle and terminal 
differentiation is a novel approach to inhibiting the progression of enhanced hyperplasia 
in childhood and adult obesity.  
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 In vitro, MCE is induced by DEX and MIX stimulation from the media. 
Growth-arrested cells, held in G0 phase, are stimulated to transition into G1 phase, 
typically within the first 12 hours, which prepares the cell for replication. In order for 
the cell to transition into S phase, when DNA replication occurs, it must first pass 
through a checkpoint to ensure the cell is in proper condition. This checkpoint between 
G1 to S phase requires the accumulation of Cyclin A within the cytosol. Cyclin A is 
part of the cyclin family, which regulates the cell cycle by binding and activating cyclin 
dependent kinases (CDKs). It is the accumulation of these complexes and individual 
proteins that allow a cell to pass through checkpoints. P27, a CDK inhibitor, binds 
cyclin and CDKs, and inhibits cell cycle progression. Therefore, if the cell is 
functioning properly, expression of p27 will be transiently down-regulated during 
checkpoint transitions, allowing cyclin-CDK complexes to accumulate. When the cell 
enters S phase, typically between 18-36 hours, it begins DNA replication. Between 36-
72 hours, the cell enters G2 phase when it prepares for final mitosis, the cleaving of two 
daughter cells. It has been shown that, during MCE events, induction of PPARγ 
increases the expression of CDK inhibitors p18 and p21, and thus shifts the cell toward 
cell cycle exit [36] which is seen typically 48-72 hours post MDI induction. 
 Reactive oxygen species (ROS) signaling is required for MCE and the addition 
of ROS enhances terminal differentiation in 3T3-L1 preadipocytes [37]. Hypertrophied 
adipocytes, incapable of managing excess ROS production, secrete excess ROS to 
surrounding tissue, stimulating precursor cells residing within the tissue to differentiate. 
This is likely the mechanism by which hyperplasia is accelerated in conditions of 
excess caloric intake, and thus explains why hypertrophy precedes hyperplasia in 
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adulthood. Therefore anti-oxidant treatment, capable of quenching excess ROS, may be 
one potential way of inhibiting hyperplasia in vivo.  
 
1.3.2 Adipocyte Metabolism 
 In a state of excess energy intake, severe hypertrophy leads to adipocyte 
dysfunction. Adipocytes can expand upwards of 100μm in diameter, nearly 10 times 
that of a typical mammalian cell. Visceral adipocytes greater than 75μm in diameter 
have been linked to the development of metabolic syndrome [38]. Therefore, 
preventing or alleviating excess lipid storage is a strategic approach in the fight against 
obesity that involves understanding how adipocytes regulate the ebb and flow of lipid 
synthesis and breakdown.  
 The primary role of adipocytes is to store energy, in the form of triglyceride, for 
times of need, such as during exercise and fasting. Circulating free fatty acids are 
readily taken up and stored as triglyceride, while excess energy in the form of glucose 
is synthesized into triglyceride through the process of de novo lipogenesis. When 
needed, adipocytes release this stored lipid into the blood stream through the process of 
lipolysis, in which triglyceride is broken down into free fatty acids (FFA) and glycerol 
that are released into the bloodstream [39]. Another fate of stored lipid is β-oxidation, 
in which the adipocyte itself uses free fatty acids to generate energy. Investigating ways 
to manipulate lipolysis and β-oxidation is an approach to reduce the amount of lipid 
stored in hypertrophied adipocytes and thus alleviate the metabolic demand they face.  
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1.3.2.1 De Novo Lipogenesis 
 Glucose is the primary source of energy for most cells. Therefore, it is readily 
metabolized through glycolysis to produce pyruvate. Pyruvate is further converted into 
acetyl-CoA, which along with citrate is a substrate for aerobic respiration. If excess 
glucose is present in the cell, acetyl-CoA and citrate will accumulate in the cytoplasm. 
This buildup metabolically shifts the cell from an energy-burning to an energy-storing 
state. Citrate buildup allosterically enhances the function of Acetyl-CoA Carboxylase 
(ACC), which converts acetyl-CoA to malonyl CoA, the substrate for lipid synthesis. 
Subsequently, the buildup of malonyl CoA inhibits the function of carnitine 
palmitoyltransferase1 (CPT1), which transports lipids across the mitochondrial 
membrane for β-oxidation. Therefore, the buildup of malonyl CoA promotes 
lipogenesis while blunting oxidation [40]. This response is one of the major ways 
adipocytes switch between energy storage and energy expenditure.  
 
1.3.2.2 Lipolysis 
 Adipocytes purge stored triglyceride through the process known as lipolysis. 
Triglyceride is stored in a lipid droplet surrounded by perilipin protein that serves as a 
protective coating. When lipolysis is activated by β-adrenergic signaling, the second 
messenger cAMP activates protein kinase A (PKA). PKA, in turn, phosphorylates 
perilipin and hormone sensitive lipase (HSL) [41]. Phosphorylated perilipin detaches 
from the lipid droplet giving phosphorylated HSL access to begin breaking down the 
stored lipid. Two other constitutively expressed lipases involved in lipolysis, 
acyltriglyceride lipase (ATGL) and monoacylglycerol lipase (MAGL), have been 
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recently discovered [39]. However, both of their activities are not as tightly regulated 
during lipolysis as that of HSL. ATGL is primarily responsible for releasing the first 
free fatty acid; HSL the second, and MAGL, the third [42]. The resulting glycerol and 
free fatty acids are transported out of the cell and into the bloodstream for other tissue 
to take up.  
 Lipolysis is of interest to anti-obesity researchers because of its ability to reduce 
lipid storage; however, the resulting increase in circulating FFA and thus potential harm 
to the circulatory system is a source of much concern.  Therefore, another approach 
involves investigating how to block the release of lipolyzed FFA from and redirect FFA 
to β-oxidation within the cell. 
 
1.3.2.3 β-oxidation 
 Lipid is the most energy dense storage unit the body has. When energy is 
needed, the body taps into this store through the process of β-oxidation, which yields 
significantly more ATPs than carbohydrate and protein metabolism. To carry out this 
process, the cell must transport FFA across the mitochondrial lipid bilayer. It does so 
through the tight regulation of carnitine palmitoyltransferase 1 (CPT1) [40], which is 
the enzyme responsible for trafficking FFA through the mitochondrial membrane. As 
mentioned previously, the build up of malonyl CoA, the substrate for de novo 
lipogenesis, allosterically inhibits CPT1. Therefore adipocytes can easily shift between 
lipid synthesis and breakdown.  
 Once in the mitochondria, fatty acid carbon chains are oxidized by niacin 
adenine dinucleotide (NAD+) and flavin adenine dinucleotide (FAD), and the 
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remaining acetyl-CoA is further degraded by the citric acid cycle. NADH and FADH2 
transport H atoms to the electron transport chain, where the build up of H atoms across 
a membrane supplies the energy for ATP synthesis. NAD and FAD are then recycled 
back for further oxidation [40].  
 A transcriptional regulator of β-oxidation is the coactivator peroxisome 
proliferator-activated receptor (PPAR)-γ coactivator (PGC)-1α. PGC-1α interacts with 
a broad range of transcription factors to regulate expression of genes related to 
metabolic processes in the cell, such as thermogenesis, mitochondrial biogenesis, and 
glucose/fatty acid metabolism. Specifically, PGC-1α is known to enhance transcription 
of Uncoupling Protein 1, which is the major thermogenic gene found in muscle cells 
and brown fat and a suggested therapeutic target for obesity treatment and prevention 
[43].   AMP- activated protein kinase (AMPK), the major metabolic regulator of the 
cell, is also known to stimulate β-oxidation and increase expression of PGC-1α to 
improve ATP/AMP ratios [44].  
 Of great interest to obesity research is the ability of mitochondria to uncouple β-
oxidation from ATP synthesis, by the use of uncoupling proteins (UCP1, 2, and 3). 
These proteins dissipate the buildup of H atoms across the inner mitochondrial 
membrane, resulting in thermogenesis instead of ATP synthesis. It has been suggested 
that adipocytes carry out a basal level of uncoupled β-oxidation that protects the body 
from fatty acid leakage, and, in the hypertrophied state, mitochondrial dysfunction 
impairs the cell’s ability to keep up with the increased flux of free fatty acids [45]. 
Therefore, finding factors that stimulate or enhance β-oxidation, and specifically 
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uncoupled β-oxidation, is a promising approach to preventing and alleviating adipocyte 
hypertrophy.  
 
1.4 The Role of AMP- activated protein kinase (AMPK) in Adipocytes 
 
1.4.1 Overview 
 When targeting obesity and the development of metabolic syndrome through 
hyperplasia and hypertrophy, it is important to consider a major metabolic regulator of 
the cell, AMP-activated protein kinase (AMPK). The function of this protein affects 
both differentiation and metabolic pathways in adipocytes.  
 AMPK is a well-known sensor of cellular ATP/AMP ratios and activation of 
AMPK shifts the cell toward an energy-producing state when ATP levels are too low. 
AMPK is comprised of 3 subunits (α, β, and γ) and is active in its phosphorylated state 
(α-subunit p-172) [46]. The γ- subunit binds AMP causing a conformational change in 
the protein that protects the α-subunit p-127 from cytosolic phosphatases [47]. 
Although AMPK activation is nearly 100-fold greater with AMP bound, AMP-
independent pathways also lead to AMPK activation. These pathways include 
calmodulin-dependent kinase kinase (CaMKK), protein kinase A (PKA), and liver 
kinase B1 (LKB1) [47]. There are several downstream targets of pAMPK, but of 
interest in adipocyte research is the phosphorylation of acetyl coenzyme A carboxylase 
(ACC), a lipogenic enzyme that is inhibited by its phosphorylation. 
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1.4.2 Activators and Inhibitors 
 The use of AMPK activators and inhibitors has allowed researchers to begin to 
understand the role of AMPK in white adipose tissue (WAT) [48-54]. The well-known 
AMPK activator, 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR), 
mimics AMP in the cell, thus activating AMPK by inducing a perceived increased 
AMP/ATP ratio. The well-known inhibitor, Compound C (CC), enzyme-specifically 
inhibits phosphorylation of p127 on the α-subunit, without altering upstream kinases.  
 
1.4.3. Role of AMPK in Adipogenesis 
 AMPK has been shown to play a critical part in adipogenesis, in particular the 
progression of mitotic clonal expansion (MCE), and is therefore a likely candidate for 
targeting hyperplasia. Habinowski et al. [49] showed that AICAR, when added at the 
initial time of differentiation in 3T3-L1 preadipocytes, inhibited differentiation as seen 
by decreased lipid accumulation and expression of adipogenic factors. They further 
demonstrated that AICAR blunted MCE, as measured by cell counting on Day 3. 
AICAR did not alter C/EBPβ expression but did inhibit PPARγ and C/EBPα, 
suggesting that AMPK activation may prevent C/EBPβ priming for DNA binding. 
Interestingly, they also found that AICAR’s effect was time-sensitive, having the 
strongest inhibitory effect when added on Day 0, a mild effect at Day 3, and no 
significant effect when added on Day 5, although this pattern has since been disputed 
[50].    
 Compound C has also been shown to inhibit adipogenesis through MCE. Gao et 
al. found that Compound Cat high concentrations (>10μM) inhibited lipid accumulation 
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and expression of PPAR γ, C/EBP α, FAS, and aP2 [55].This effect was limited to early 
time points as treatment after the first two days of differentiation had no impact on lipid 
accumulation or adipogenic factors.  Further, Compound C treatment decreased cell 
number from Day 0 to Day 3 of differentiation.  Nam et al. also found Compound C 
inhibited adipogenesis through MCE, as Compound C increased levels of p21, a cyclin 
kinase dependent inhibitor, levels [53].  
 Taken together, the general consensus in the literature is that either activation or 
inhibition of AMPK alters MCE events and inhibit adipogenesis. This effect is 
understandable, as the cell’s energy needs must be tightly regulated during such a 
demanding transition. Therefore, identifying factors that target AMPK are of interest in 
preventing hyperplasia. Interestingly several researchers have shown that certain 
bioactive compounds exert their anti-adipogenic effect through AMPK activation [47, 
56]. 
 
1.4.4 Role of AMPK in Mature Adipocytes 
 Much interest surrounds the role of AMPK in the metabolism of mature 
adipocytes. Specifically, activation of AMPK to induce lipolysis and increase 
mitochondrial oxidation of fatty acids would lead to a possible approach to alleviate 
hypertrophy. 
 In general, activated AMPK turns on catabolic pathways that produce ATP and 
turns off anabolic pathways that consume ATP. Likewise, it has been shown that 
AMPK increases β-oxidation in muscle and liver cells [57], but the effect on adipocytes 
remains unclear. In theory, AMPK activation would activate oxidative pathways while 
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inhibiting lipid synthesis. It is known that AMPK phosphorylates and deactivates the 
lipid synthesizing enzyme ACC, resulting in a cytosolic decrease in malonyl CoA. This 
decrease subsequently results in the availability of CPT1 to transfer fatty acids into the 
mitochondria, thus shifting the cell toward β-oxidation. Gaidhu et al. [58] found these 
effects in isolated epididymal rat adipocytes. Their findings showed that chronic 
AICAR exposure (15hours) increased pACC, fatty acid oxidation, and PGC-1α, CPT1, 
acetyl-CoA oxidase mRNA expression, while UCP1 and UCP2 were unaltered by 
AICAR treatment. The authors concluded that AMPK activation could remodel 
adipocytes toward energy dissipation.  
 Also of particular interest is AMPK’s effect on lipolysis.  Upon normal β-
adrenergic stimulation of lipolysis, cAMP activates PKA, which in turn phosphorylates 
and activates HSL for lipolysis. Djouder et al. found that PKA concurrently inactivates 
AMPK in order to promote efficient lipolysis [59]. However other researchers have 
found that AMPK activation through cAMP was necessary for induced lipolysis, as 
lipolysis was no longer stimulated in the presence of mutant AMPK alpha subunits [60]. 
When AMPK was therapeutically activated by the use of AICAR in isolated rat 
adipocytes, AICAR inhibited HSL activation and glycerol release, but over the course 
of 15 hrs increased FFA release [52]. The authors here concluded that the length of 
AMPK activation determined the lipolytic response; acute treatment resulted in an 
inhibition of lipolysis, while chronic activation resulted in an increase of fatty acid 
release. This difference may explain some of the controversy observed among 
researchers. Because glycerol release did not also increase with time, the authors 
suggested that AMPK activation may prevent the complete hydrolysis of triglyceride 
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molecules through the inhibition of HSL phosphorylation.. If triglyceride hydrolysis is 
incomplete triglycerides are broken down to diacylglycerides by ATGL but not further, 
resulting in the release of some FFA and the shunting of diacylglycerides to other 
metabolic pathways in the cell. This provides a potential mechanism and indicates that 
AMPK may play a critical role in the cells ability to undergo lipolysis. 
 AMPK regulation provides a promising new avenue toward alleviating 
adipocyte hypertrophy as it has been implicated in β-oxidation and lipolysis. Recently, 
several bioactive compounds have been implicated as AMPK activators [16], which 
could provide a natural approach toward targeting hyperplasia and hypertrophy in the 
progression of obesity.  
 
1.5 Potential Health Effects of Bioactive Compounds in the Development of 
Obesity 
 
 To prevent chronic disease, increasing fruit and vegetable consumption has been 
the longstanding advice. Consistently, fruit and vegetable intake is negatively 
correlated with the occurrence of obesity and metabolic syndrome [61, 62], and further, 
increasing fruit and vegetable consumption may decreases risk for heart disease and 
diabetes [63, 64]. Not only do fruits and vegetables provide a low-calorie, high-fiber 
option, but researchers within the past several decades have also identified more than 
thousands of phytochemicals that naturally occur in the produce we eat [65]. Discovery 
of bioactive compounds has invited researchers to explore the vast array of beneficial 
effects these compounds possess. Much interest surrounds the use of bioactive 
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compounds, through increased consumption and supplementation, to prevent or 
alleviate symptoms of metabolic syndrome as drug therapy is not only costly, but often 
elicits negative side-effects [4, 66].  
Currently, it is estimated that humans consume about 1-3g of bioactive 
compounds daily, depending on their level of fruit and vegetable intake [67]. Nearly all 
bioactive compounds have been shown to possess health-promoting properties, 
typically in a dose-dependent manner. The American Dietetic Association (ADA) 
acknowledges the significance of consumption of bioactive compounds and therefore 
supports the marketing of functional foods, either conventional or modified, when there 
is substantial scientific evidence of benefit [68]. Flavonoids, a sub group of 
polyphenols, are currently a top priority of research efforts to The National Institute of 
Health’s National Center for Complimentary and Alternative Medicine (NCCAM) 
because the health benefits shown. Specifically, the flavonoid quercetin is of great 
interest because of its suggested ability to alleviate obesity-related conditions [67]. 
 
1.6 The Dietary Flavonoid Quercetin 
 
1.6.1 Overview 
 Flavonoids are a class of phytochemicals, 
discovered in the 1930s, that generate pigment in 
plants and play a biological role in other cellular 
processes. It is estimated that the average dietary 
intake of flavonoids in humans is several hundred               Figure 1. Structure of Quercetin 
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milligrams per day [65].   
 Quercetin, the most abundant dietary flavonoid, has been the focus of 30 years 
of research for its strong antioxidant capabilities. It is a flavonol, one of the five 
subclasses of flavonoids, and it’s ring structure and aglycone configuration of hydroxyl 
groups, make it one of the most potent flavonoids in terms of antioxidant capabilities 
[69, 70]. Quercetin is found in numerous fruits and vegetables but the major dietary 
sources include onion, red apples, red wine, tea, 
cranberry, kale, hot peppers and broccoli [71]. 
Determining exact amounts of flavonoid content 
in any plant is very challenging because flavonoid 
production is affected by sunlight, environmental 
factors, degree of ripeness, and species genetic 
variability [72]. Further quercetin is stored in the 
skin of most fruits and vegetables, therefore content can very significantly depending 
on skin to overall weight ratio. Consequently, estimating quercetin intakes through 
dietary analysis is particularly limited, making it difficult to complete epidemiological 
studies relating quercetin intake to chronic disease [65]. Estimated quercetin intakes 
range from 10-100mg per day depending on an individual’s consumption of these fruits 
and vegetables [67]. It could be speculated that 6-8 servings of fruits and vegetables 
daily would provide an average daily consumption of 100mg quercetin, however as 
discussed, exact quercetin content data is limited. Higher levels of intake between 
500mg-1200mg can be safely achieved by the use of supplements (this amount would 
be likely be comparable to consumption of 5-10 times the recommended servings, 6-8, 
Table 1. Sources of Quercetin 
Food Source   Amount ( mg/kg) 
 
Onions       284-486 
Kale       110 
Asparagus      142 
Apple       21-72 
Green Beans       39 
Cherry Tomatoes      17-200 
Broccoli       30 
Tea       10-25 
Red Wine      4-16   
            Modified from Manach, 2005 [71] 
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of fruits and vegetable, and could only be achieved through supplementation).  
Researchers are thus trying to utilize the potential of this readily available flavonoid 
through increased consumption and supplementation for its antioxidant, anti-
inflammatory, and anti-proliferative properties [67, 73].  
 
1.6.2 Bioavailability 
 As with any bioactive compound, bioavailability is of great interest and 
importance. Quercetin is predominantly found in nature in variations of its glycoside 
form: either quercetin 3-O-β-D-glucoside (Q3G) or quercetin 4’-O-β-D-glucoside 
(Q4G) [74]. These forms are useful to the plant because of their water-soluble 
properties, but do not have the same antioxidant capabilities of the aglycone form, and 
are thought to be metabolized by the gut microflora before absorption. Three factors 
that determine the bioavailability of quercetin: (1) metabolism by gut microflora, (2) 
transport through small intestinal cells, and (3) final circulating metabolites.  Although 
the question of which metabolites are absorbed and circulate remains controversial, 
advancements in detection methods have come a long way since 1975, when Gugler et 
al. [75] first gloomily reported the quercetin doses did not alter plasma levels in humans. 
 
1.6.3 Gut Metabolism 
 It is estimated that 9 out of 10 cells in the body are bacterial [76], which puts in 
perspective the influence of an individual’s gut microflora on digestion and gut 
metabolism.  Specifically, it has been well demonstrated that gut bacteria are capable of 
degrading quercetin into phenolic acids and CO2, methylating aglycone compounds, 
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and hydrolyzing quercetin glucosides [77]. Chen et al. [78] determined in rats that 
93.3% of absorbed quercetin had been metabolized by the gut and only 3% by the liver 
after absorption. They also showed that 60% of total ingested quercetin was absorbed. 
Earlier studies done by Hollman et al. [79, 80] indicated that a dose of quercetin in 
glucoside form was better absorbed than the aglycone, as measured by ileostomy 
effluent content of glucosides. In stark contrast, Walgren et al. [81] showed, using a 
Caco-2 cell monolayer, that aglycones are more readily transported across the intestinal 
layer than glucosides. Walle et al. [82] aimed to address this conflict and discovered 
that glucosides in an onion meal are effectively hydrolyzed to the aglycone form, which 
can be absorbed. These findings suggest that nearly all excreted quercetin is aglycone 
and further that we rely on gut bacteria to hydrolyze dietary quercetin for absorption. 
This explains why significant variation may exist among individuals in their ability to 
absorb quercetin based on the make up of their gut microflora.  
 
1.6.4  Absorption and Transport 
 Piskula and Terao [83] were among the first, along with Manach [84], to 
demonstrate that quercetin doses in rats result in plasma metabolite concentrations of 1-
2µM. Their findings further suggested that absorption was affected by the solubility of 
quercetin in the vehicle of administration (quercetin dissolved in propylene glycol 
resulted in plasma concentration of 50µM). Human supplementation studies typically 
result in a total plasma quercetin metabolite range of 10-200nM [77].  The most 
common detection method for plasma quercetin digests all the quercetin metabolites 
and provides an overall concentration. With more sensitive techniques, researchers are 
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trying to determine which metabolites, specifically aglycone verses glucosides, 
circulate at higher levels, as this would likely be the metabolite that exerts an effect on 
tissues. The pertinent body of research remains inconclusive, according to a recent 
review, as some researchers indicated that quercetin glucoside forms were detected in 
plasma [85, 86], and others reported that aglycone forms but not glucosides were 
present [87, 88]. Other studies have shown a wide range of quercetin metabolites 
detected in the plasma [89]. Because of the significant in vitro findings of quercetin 
aglycone, work is currently underway to develop nanoparticle vehicles that protect 
quercetin from gut and liver metabolism and therefore deliver it in its potent aglycone 
form to tissues [73].  
 Because it is reasonable to postulate that both aglycone and glucoside forms 
circulate in the plasma, it is of interest to study the effect of both metabolites on adipose 
tissue. However the scope of research in this study focuses on the aglycone form. 
Although concentration ranges used in this study are higher than physiological 
concentrations, as compared to what is observed in vivo after supplementation (10-
200nM), it is relevant for our work in less sensitive cell culture systems to observe the 
molecular changes that occur in response to quercetin.   
 
1.7 Quercetin’s Effect on Metabolic Syndrome: In Vivo Studies 
 
 Quercetin is currently of great interest to researchers because of significant in 
vivo animal studies showing its ability to ameliorate metabolic syndrome. Vessal et al. 
[6] found that in streptozocin (STZ)-induced diabetic rats (a model that is comparable 
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to type 1 diabetics), doses of 10mg/kg and 15mg/kg per day, began to lower blood 
glucose levels after only 3 days and had completely normalized blood sugar levels after 
10 days. The authors concluded that quercetin may be able to stimulate pancreatic islet 
cell regeneration. In 2008, Rivera et al. [7], found that quercetin doses (2 or 10 mg/kg) 
ameliorated high plasma concentrations of triglycerides, total cholesterol, FFA, and 
insulin in Zucker rats, and further that the higher dose increased plasma concentrations 
of adiponectin, reduced NOx levels in plasma, and lowered VAT TNF-alpha production. 
Kobori et al. [8] fed mice a diet high in fat, cholesterol, and sugar for 20 weeks, and 
supplemented one group with 0.05% quercetin. After the 20-week period, 
supplemented mice had plasma quercetin levels of 14.16μM, and had significantly less 
fat accumulation in the liver, reduced circulating triglyceride levels, and improved 
blood glucose and insulin levels. The same group had previously found quercetin-fed 
(0.1% or 0.5%) streptozotocin (STZ)-induced diabetic mice had improved blood 
glucose and plasma insulin levels [9]. Bansal et al. [10] showed similar results feeding 
STZ-induced mice a high-fat diet with Pileamicrophylla (PM1), a plant containing 
quercetin, among other flavonoids. PM1 at a dose of 100 mg/kg/day, for 28 days 
produced significant (p<0.05) reduction in body weight, plasma glucose, triglycerides, 
and total cholesterol content. It is important to note, due to the complexity of quercetin 
bioavailability, significant results are not always found with varying quercetin doses 
[90]. However, the majority of animal studies to date strongly suggest quercetin as an 
anti-obesity, insulin-sensitizing agent, warranting further research.  
 Human trials show promising preliminary results. Egert et al., in a randomized 
double-blinded, placebo-controlled cross-over trial gave overweight and obese subjects 
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150mg dose of quercetin daily for 6 weeks (resulting in plasma quercetin levels of 71 to 
269 nM/l). Quercetin treatment decreased systolic blood pressure (-2.6 mmHg, 
p<0.001), oxidized LDL levels, and, interestingly, HDL levels, when compared to the 
placebo group [91]. Further, this group retrospectively characterized the effect of 
quercetin on serum blood pressure and lipid profile to be linked to variations in 
apolipoproteinepsilon genotype [92], suggesting an explanation for varied responses to 
quercetin treatment. Although some supplementation studies have shown no significant 
effect [93, 94], this is likely due to dosage, study duration,  poor bioavailability, and 
variable gut microflora of each individual. Therefore, optimizing study design is 
essential in human supplementation trials.  
 These significant in vivo findings command further mechanistic research of 
quercetin’s effect at the cellular level, specifically in the areas of hyperplasia and 
hypertrophy as both lead to the development of metabolic syndrome. Current research 
detailing what is known about both quercetin’s effect on adipogenesis and adipocyte 
metabolism, as well as our recent findings, are described below in Chapters 2 and 3, 
respectively.  
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CHAPTER 2 
EFFECT OF QUERCETIN ON ADIPOGENESIS 
 
2.1 Literature Review 
 
 The rise in obesity will significantly decrease life expectancy and continue to 
burden health care systems because of increased risk for the development of chronic 
diseases [95]. On a cellular level, obesity is defined as the increase in size 
(hypertrophy) and number (hyperplasia) of adipocytes. Studies have shown that 
adipocyte number is determined during childhood and maintained through adulthood, 
emphasizing the importance of preventing childhood obesity. In adulthood, hypertrophy 
precedes hyperplasia to accommodate initial excess energy intake, however as excess 
intake persists, such as in the development of obesity,  hyperplasia is accelerated [23, 
25]. Further, weight loss results in a reduction in adipocyte volume but not necessarily 
adipocyte number [2]. Adipocytes are extremely resistant to apoptosis; therefore 
adipose tissue that has been expanded by hyperplasia will be maintained, making it 
harder for an individual to sustain weight loss and worsening the prognosis for 
treatment [26, 27]. Targeting hyperplasia is thus essential for preventing the 
progression of childhood and adult obesity.   
 Several bioactive compounds have been shown to inhibit adipogenesis, the 
process of developing new adipocytes. Quercetin, the most commonly consumed 
flavonoid, is one such compound. Because quercetin is known to have anti-proliferative 
and apoptotic properties, it was first hypothesized to inhibit preadipocyte growth. Hsu 
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et al. [96] ,while comparing the effects of various flavonoids on undifferentiated 3T3-
L1 pre-adipocytes, found that quercetin most strongly inhibited cell population growth 
and induced cell apoptosis through caspase-3 in a dose-dependent manner (50-250μM). 
Quercetin was also found to be anti-proliferative in human stromal cells  [97]. Park et al. 
[11] showed that quercetin, alone or in combination with genistein and resveratrol 
inhibited lipid accumulation in differentiating 3T3-L1 and human adipocytes. Similar 
results were also found by Yang et al. [12] who determined in 3T3-L1 cells that 
quercetin (25μM) alone inhibited lipid accumulation by 15.9+/-2.5% (p<0.001), and in 
combination with resveratrol (25μM) inhibited lipid accumulation by 68.6+/-0.7% 
(p<0.001). Although it is generally agreed that quercetin is anti-adipogenic, Morikawa 
[98] interestingly showed that quercetin induced apoptotic genes without inhibiting 
PPARγ and fatty acid synthase (FAS) during differentiation of human preadipocytes, 
suggesting quercetin may work through PPARγ-independent pathways. 
 One potential mechanism for quercetin’s anti-adipogenic effect was recently 
proposed by Ahn et al. in 2008 [13]. They reported that differentiating 3T3-L1 cells in 
the presence of quercetin (10-100μM) decreased lipid accumulation and expression of 
adipogenic factors (CEBPα, PPARγ, SREBP-1, FAS). They further looked at the 
effects of quercetin during differentiation on AMP-activated protein kinase (AMPK), 
the metabolic regulator of the cell, and its down stream target acetyl-CoA carboxylase 
(ACC), and found that phosphorylation of both of these proteins by Day 8 was 
increased in the presence of higher concentrations of quercetin (50μM and 100μM). 
The authors suggested AMPK activation as a potential mechanism for quercetin’s anti-
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adipogenic effect. The role of AMPK activation during differentiation has been 
considered anti-adipogenic [49] and potentially regulates mitotic clonal expansion. 
 Mitotic clonal expansion (MCE) has been implicated as a critical regulator of 
adipogenesis in vivo and is a current targeted pharmacological approach in the fight 
against obesity [25]. Cell cycle is tightly regulated by transitory cyclin dependent 
kinases and kinase inhibitors, two of which are Cyclin A and p27, respectively. The 
abolishment of p27 in vivo lead to increased proliferation and recruitment of 
preadipocytes [35]. .MCE has been shown to be necessary for terminal differentiation 
in vitro in 3T3-L1 preadipocytes [99]. Given quercetin’s anti-proliferative properties, 
and ability to activate AMPK, it is logical to hypothesize that quercetin may inhibit 
adipogenesis through altering cell cycle events; however this effect has never been 
explored.  
 Understanding this mechanism will help develop quercetin as an anti-obesity 
agent because of its ability to target hyperplasia, a critical process in the development 
of obesity and metabolic syndrome. 
 
2.2 Purpose of Study 
 
 Given the current gap in the literature surrounding quercetin’s ability to inhibit 
adipogenesis through mitotic clonal expansion, and the significance these findings 
would have on the development of quercetin as an anti-obesity agent, we aimed to fill 
this gap by determining (1) quercetin’s effect on adipogenesis using  3T3-L1 
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preadipocytes, and (2) quercetin’s effect on cell number and cell cycle related genes 
Cyclin A and p27, key regulators for cell cycle progression from G1 phase to S phase.  
 Our hypothesis was that quercetin will (1) inhibit lipid accumulation, as 
measured by Oil Red O staining, and expression of adipogenic factors PPARγ, C/EBPα, 
aP2, ACC on the mRNA and protein levels, and (2) inhibit cell number, a measure of 
mitotic clonal expansion, and alter mRNA expression of Cyclin A and p27 when 
analyzed at 0-48 hours.  
 
2.3 Materials and Methods 
 
2.3.1 Cell Culture Model and Treatments 
For the differentiation of 3T3-L1 preadipocytes, cells were grown to 100% confluence 
in Growth Media [DMEM (high glucose), 10% Calf Serum, 1% Penicilin/ 
Streptamycin] replaced every two days. At two days post-confluence, growth media 
was changed to Differentiation Media [DMEM (high glucose), 10% Fetal Bovine 
Serum, 1% P/S, 1% Insulin, 1% 3-Isobutyl-1-methylxanthine 11.5mg/ml, 0.01% 
Dexamethasone 3.9mg/ml] in the presence or absence of quercetin aglycone (Sigma-
Aldrich Catalog # 6151-25-3). The combination of 3-Isobutyl-1-methylxanthine (MIX), 
dexamethasone, and insulin is known as the standard MDI adipogenic cocktail. At two 
days post-MDI induction, media was replaced every two days with post-differentiation 
media [DMEM (high glucose), 10% Fetal Bovine Serum, 1% P/S, 1% Insulin, +/- 
quercetin]. 3T3-L1 preadipocytes generally reach 80% differentiation 4 to 5 days post-
differentiation.  
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2.3.2 Oil Red O Lipid Staining   
Cells were harvested on desired days and underwent Oil Red O Staining to quantify 
lipid accumulation, as it is an indirect determiner of cell differentiation. Cells, grown on 
24-well and 6-well plates, were treated with 10% formaldehyde in phosphate buffer 
solution (PBS) for 1 hour, washed with 60% isopropanol, and completely dried. Then, 
cells were stained with 0.5% Oil Red O solution in 60:40 (v/v) isopropanol: H2O, for 
30 minutes at room temperature. Finally, wells were rinsed with distilled water and 
dried. Optical density was then measured at 490nm, after eluting with isopropanol, to 
quantify lipid accumulation. 
 
2.3.3 Cell Viability and Counting 
Cells were grown to confluence in 24-well plates. At two-days post-confluence cells 
were differentiated with MDI in the presence or absence of quercetin (25 and 50μM). 
Media was replaced, two days later, with post-differentiation media (treatment 
continued). On day 3, cells were prepared for Trypan Blue staining. Media was 
removed and wells were washed with PBS. Trypsin was added to each well (0.25ml) 
and let sit for 10 minutes to ensure cell detachment. PBS (0.75ml) was then added to 
bring cell suspension volume to 1ml. Trypan Blue (modified) 0.4% solution 1N PBS 
(from MP Biomedical Inc, cat# 1691049) was added to cell suspension (1:1) in a fresh 
centrifuge tube for 3 minutes. A hemocytometer was used to count cells from each well 
twice. Each treatment had 6 replicate wells. Both stained and unstained cells were 
counted (stained cells are non-viable). Cells were counted in the 4 corners of the 
hemocytometer, and total cell number was calculated as (total of 4 squares) x (2500) x 
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(2 dilution factor). Percent viable equaled the number of viable cells divided by total 
cell number (viable plus non viable counts).  Total viable cell number was the average 
number of unstained cells from each treatment replicate. 
 
2.3.4 Protein Isolation and Western Blotting 
Cells were harvested at desired times with RIPA Buffer containing protease inhibitor 
(500ul per p-100 dish). Samples were stored at -80° C until protein quantification. 
Samples were thawed on ice, sonicated, and centrifuged. Supernatant, containing whole 
cell protein, was transferred to a fresh tube for protein quantification using the 
Bicinchoninic Acid (BCA) assay. A BCA standard curve was established using bovine 
serum albumin (BSA)[2mg/ml] protein and measured at 570nm. Sample concentrations 
were then measured against the standard, and prepared with sample buffer to allow for 
15μg to be loaded to the gel. Samples were run on acrylamide (varying percentages) 
gels via electrophoresis, and then proteins were transferred to a PVDF membrane 
through wet transfer. Upon successful transfer, membranes were blocked with 5% non-
fat dry milk, and treated with primary and secondary antibodies (purchased from Santa 
Cruz Biological). HRP detection was done through ECL solution. Chemiluminescent   
bands were captured on x-ray and developed.   
 
2.3.5 RNA Isolation and Analysis 
Cells washed with phosphate buffer solution (PBS), were harvested with Trizol 
Reagant and stored at -80° C until mRNA isolation. For isolation, samples were thawed 
and centrifuged with 200µL chloroform.  Supernatant was transferred to a fresh tube 
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and centrifuged with isopropanol (1:1) to precipitate RNA. Isopropanol was removed 
and the pellet was washed three times with ethanol by centrifugation. The pellet was 
then resuspended in DEPC water and quantified using a spectrophotometer at 260nm.  
8µg of RNA was used along with SuperScript III reagents to make cDNA which was 
stored at -4°C. Polymerase Chain Reaction was performed with primers for PPARγ, 
C/EBPα, aP2, Cyclin A, and β (see Table 2). Samples were run on an agarose gel 
containing Ethidium Bromide, and detected using Ultra Violet light. Band intensity was 
determined using Image J analysis and adjusted to β-actin. 
Table 2.  Primer Information  
 
 
2.3.6 Statistical Analysis 
Samples were collected in at least duplicate or triplicate, and differences between the 
means were determined by student’s T-test. P-values were considered significant at 
<0.05.  
 
 
Primer              Forward Sequence                      Reverse Sequence     Temp/Cycles 
ACCα         5’-CCCAGCAGAATAAAGCTACTTTGG-3’   5’-TGAGCATGGCATCCGGCGACT-3’           58°C / 40  
Adiponectin  5’-AAGGACAAGGCCGTTCTCT-3’        5’-TATGGGTAGTTGCAGTCAGTTGG-3’        56°C / 35 
aP2   5’-GACCTGGAAACTCGTCTCCA-3’             5’-CATGACACATTCCACCACCA-3’                56°C / 30 
β-actin      5’-AGGCTGTGCTGTCCCTGTATGC-3’           5’-ACCCAAGAAGGAAGGCTGGAAA-3’        61°C / 35 
C/EBPα  5’-GGTGCGCAAGAGCCGAGATAAAG-3’       5’-AGTTCACGGCTCAGCTGTTCCAC-3’         61°C / 35 
Cyclin A 5’GCAGTTTTGAATCACCACATGCATGCCGGGCACCTCGAGGCAT-3’  5’-TGGCTGCCTCTTCATGTAACCTCACACACTTAGTGTCTCTGGTG-3’  63°C / 35 
GAPDH   5’-CAAGGTCATCCATGACAACTTTG-3’        5’-GGCCATCCACAGTCTTCTGG-3’                60°C / 35 
NOX4  5’-GAAGCCCATTTGAGGAGTCA-3’        5’-GGGTCCACAGCAGAAAACTC-3’               56°C / 35 
PGC-1α   5’-TGGACGGAAGCAATTTTTCA-3’        5’-TTACCTGCGCAAGCTTCTCT-3’                56°C / 35 
PPARγ     5’-CCAGAGTCTGCTGATCTGCG-3’                 5’-GCCACCTCTTTGCTCTGATC-3’                 58°C / 40 
UCP-1      5’-ATACTGGCAGATGACGTCCC-3’        5’-GTACATGGACATCGCACAGC-3’               59°C / 35 
UCP-3     5’-ACTCCAGCGTCGCCATCAGGATTCT-3’  5’-TAAACAGGTGAGACTCCAGCAACTT-3’   59°C / 35 
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2.4 Results 
 
2.4.1 Quercetin inhibits lipid accumulation and adipogenic transcriptional factors 
3T3-L1 pre-adipocytes were stimulated to differentiate at Day 0 in the presence of 
increasing concentrations of quercetin (0-100μM). By Day 8 of differentiation 
quercetin dose-dependently inhibited lipid accumulation (Figure 2). (Troglitazone, a 
PPAR γ ligand, was used as a positive control to demonstrate the ability of our model 
system to be stimulated toward differentiation.) Further we determined quercetin 
inhibited mRNA expression of PPAR γ (1.1 fold), C/EBP α (17.6 fold), aP2 (2.1 fold) 
(Figure 3) and protein expression of PPAR γ, and ACC  (Figures 4). These results 
indicate that quercetin inhibits adipogenesis in our model system through the inhibition 
of critical transcriptional adipogenic factors. 
 
2.4.2 Quercetin’s inhibitory effect is limited to early time points 
Mitotic clonal expansion (MCE) occurs in 3T3-L1 preadipocytes between Day 0 and 
Day 3 after MDI stimulation. Because quercetin is known to be a strong anti-
proliferative agent and AMPK activator, we tested the hypothesis that quercetin’s effect 
on lipid accumulation is limited to treatment during early time points of differentiation. 
Quercetin treatment was staggered, with treatments starting at 0, 6, 12, 18, 24, 36, 48, 
72 hours after MDI stimulation at time 0 hour. All treatments were continued until Day 
6 of differentiation when cells were harvested for Oil Red O staining. Quercetin’s 
strongest inhibitory effect was observed when added between 0-18hours (Figure 5). 
Quercetin treatment starting at 24-36 hours still significantly inhibited lipid 
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accumulation as compared to the control, however after 48 hours quercetin had no 
significant effect. This finding indicates quercetin’s effect is limited to early time points 
of adipogenesis. 
 
2.4.3 Quercetin may inhibit adipogenesis through regulation of early cell cycle events 
We further investigated quercetin’s effect on mitotic clonal expansion by looking at cell 
number and cell cycle related genes. Figure 6a shows that between Day 0 and 3, cell 
number dramatically increases. Quercetin significantly inhibited total cell number in 
this trial. We next repeated this experiment using Trypan Blue staining to detect viable 
and non-viable cells, and only looked at Day 3 counts since they reflect the end of MCE. 
Quercetin treatment did not alter the % of viable cells indicating quercetin’s effect is 
not cytotoxic. Although not significant, there was a clear trend indicating quercetin may 
decrease viable cell number at Day 3. This suggests quercetin may inhibit MCE. We 
next looked at cell cycle genes Cyclin A, a positive regulator of cell cycle, and p27, an 
inhibitory regulatory of cell cycle. In preadipocytes stimulated to differentiate at time 0 
hour, Cyclin A mRNA rose at 12 hours and fell by 24 hours in the control. However 
quercetin (50µM) treatment inhibited Cyclin A expression at 12 and 24 hours, delaying 
Cyclin A induction until 36 and 48 hours (Figure 7). Quercetin treatment also altered 
the expression of p27.  Preadipocytes stimulated to differentiate at time 0 hour 
transiently decreased protein expression of p27 between 18-24 hours. Quercetin 
(50µM) sustained p27 expression through the mitotic clonal expansion period (Figure 
8).  
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Figure 2. Quercetin dose-dependently inhibits lipid accumulation. 3T3-L1 
preadipocytes were differentiated in the presence or absence of quercetin (10-
100µM), and harvested at Day 0, 4, and 8 for Oil Red O staining to measure lipid 
accumulation. Troglitazone (Tro), a PPARγ ligand, was used as a positive control. 
Compared to the control (CON) with just MDI differentiation media, quercetin 
treatment 50 and 100µM significantly decreased lipid accumulation dose-
dependently at Day 4 and Day 8 of adipogenesis.  
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Figure 3. Quercetin inhibits adipogenic factors at the mRNA level. 3T3-L1 
preadipocytes were differentiated in the presence or absence of quercetin (10-
100µM), and harvested at Day 8 for mRNA analysis, by qualitative PCR. The 
major adipogenic regulators, PPARγ, C/EBPα, and their target gene aP2 all 
increased in the control from Day 0 to Day 8. Quercetin treatment dose-
dependently inhibited expression of these factors by Day 8, indicating quercetin 
inhibits adipogenesis through the down regulation of adipogenic transcription 
regulators.   
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Figure 4. Quercetin inhibits adipogenic factors at the protein level. 3T3-L1 
preadipocytes were differentiated in the presence or absence of quercetin (50µM), 
and harvested at sequential time points (0, 12, 24, 48, 72 hours, and Day 6) for 
protein analysis. Acetyl-CoA Carboxylase (ACC), an enzyme responsible for lipid 
synthesis, and PPARγ, the transcriptional regulator of adipogenesis both increased 
in the control over the course of adipogenesis. Quercetin treatment (50µM) 
inhibited the increase of expression in both these adipogenic factors, especially the 
induction around 24 and 48 hours.  
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Figure 5.  Quercetin’s inhibitory effect on lipid accumulation is limited to 
early time points. 3T3-L1 preadipocytes were stimulated to differentiate at time 
0 hour. Quercetin was added to differentiating media at subsequent times (0, 6, 
12, 18, 24, 36, 48, and 72 hours) and continued through the duration of the 
experiment until Day 6 when all cells were harvested for Oil Red O staining to 
measure lipid accumulation. Quercetin inhibited lipid accumulation strongest 
when added between 0-18 hours, less but still significant at 24-36 hours, and no 
effect if added after 48 hours. These results indicate quercetin’s anti-adipogenic 
effect is limited to early events of adipogenesis. 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell Viability
Treatment
Con Q10 Q20 Q50
%
 o
f C
on
tr
ol
0
20
40
60
80
100
120
Total Viable Cells
Treatment
Con Q10 Q20 Q50
C
el
l N
um
be
r
0
20000
40000
60000
80000
Figure 6.  Quercetin does not affect cell viability but may inhibit cell number. 
Mitotic clonal expansion (MCE) occurs between Day 0-3 of differentiation in 3T3-
L1 preadipocytes, dramatically increasing the number of cells in a well 2 or 3 fold 
by Day 3. (A) Trial 1: Cells were differentiated and harvested  at 0, 24, 48, and 72 
hours for cell counting by hemocytometer (n=3). The control clearly increased over 
72hours. Quercetin significantly inhibited cell number at 24 and 72 hours. (B and C) 
Trial 2: Cells were differentiated in the presence or absence of quercetin (50µM) and 
harvested at Day 3 for Trypan Blue staining and counting by hemocytometer (n=6). 
Viable and non-viable cells were counted and % viable was determined by # of 
viable cells/ #of total cell, indicating the percent of living cells at Day 3. Quercetin 
treatment did not alter the % viable, indicating quercetin’s effect is not cytotoxic. 
Although not significant, there was a clear trend indicating quercetin may decrease 
cell number at Day 3. Trypan Blue staining allows for the detection between viable 
and non viable and was thus employed during the second trial. 
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Figure 7. Quercetin delays mRNA expression of Cyclin A during early stages 
of adipogenesis. During mitosis, Cyclin A accumulates to regulate the transition 
from G0 to S phase.  In 3T3-L1 preadipocytes stimulated to differentiate at time 0 
hour, Cyclin A mRNA rose at 12 hours and fell by 24 hours. However quercetin 
(50µM) treatment, at time 0 hour, inhibited Cyclin A expression at 12 and 24 
hours, delaying Cyclin A induction until 36 and 48 hours. A possible explanation 
is that quercetin is able to blunt reactive oxygen species signaling that is required 
for the stimulation of cell cycle during the first 24 hours but losses its anti-oxidant 
capacity by 36 hours allowing Cyclin A to accumulate. Thus, this data suggests 
quercetin is able to alter normal cell cycle events. 
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Figure 8. Quercetin sustains protein expression of P27 during the early 
stages of adipogenesis. P27 is a cyclin dependent kinase inhibitor that inhibits 
cell cycle progression. Cells undergoing mitosis transiently down regulate this 
protein to allow the transition from G0 to S phase. Preadipocytes stimulated to 
differentiate at time 0 hour transiently decreased protein expression of p27 
between 18-24 hours. Quercetin (50µM) sustained p27 expression through the 
mitotic clonal expansion period. This data suggests quercetin inhibits the 
progression of cell cycle. 
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2.5 Discussion 
 
 Adipogenesis has been identified as a critical target in the progression of obesity 
and metabolic syndrome. In our model system, quercetin inhibited adipogenesis as seen 
by the inhibition of lipid accumulation and adipogenic factors at the mRNA and protein 
level. Our findings further suggest that quercetin may inhibit adipogenesis through 
altering early mitotic clonal expansion (MCE) events, as (1) quercetin’s effect was 
limited to the early stages of adipogenesis (0-36 hours), (2) quercetin treatment tended 
to inhibit cell number, and (3) quercetin treatment altered the normal expression pattern 
of cell cycle related genes Cyclin A and p27.   
 During normal MDI stimulation, cells undergo several rounds of replication 
between Day 0 and Day 3 and dramatically increase cell number on the plate, as seen in 
Figure 6a. Quercetin significantly inhibited total cell # counts, but total viable cell 
counts from our second trial using Trypan Blue staining did not show significance. 
Although not significant, cell number counts showed a clear trend that quercetin 
inhibited cell number while not altering cell viability. We attribute the lack of 
significance to the limitation of counting by hemocytometer, which is a rough estimate 
of cell number. To obtain more accurate cell counts an automated device such as 
NucleoCounter, should be used.  
 Cyclin A and p27 regulate the transition from G0 to S phase in the cell cycle. 
Our findings indicate that quercetin altered this cell cycle regulation particularly 
between 6-18 hours post-MDI induction. Quercetin treatment delayed Cyclin A 
expression until 36 hours, where expression is then markedly increased. One possible 
explanation for this late onset is that over the first 24 hours of treatment quercetin was 
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able to quench reactive oxygen species (ROS) signaling necessary for the induction of 
cell cycle events [37], however, by the end of 24 hours quercetin’s antioxidant capacity 
was depleted allowing the cell to mount one final attempt at cell cycle progression. We 
have further shown in preliminary data (see Appendix 1) that quercetin inhibits the 
mRNA expression of NADPH oxidase 4 (NOX4), a mitochondrial protein responsible 
for producing ROS required for differentiation [100]. Nonetheless, it is clear that 
quercetin prevented early induction of Cyclin A which facilitates the transition from S 
phase into G2 phase. To further determine quercetin’s effect on cell cycle, Flow 
Cytometry should be employed to provide a quantitative profile of the number cells in 
each cell cycle stage.  
 MCE has been implicated to be required for terminal differentiation in 3T3-L1 
adipocytes. 3T3-L1 pre-adipocytes in the presence of a mitotic inhibitor fail to 
differentiate [99]. However, other adipogenic models (10T1/2 MSCs, and Human 
MSCs) have been shown to differentiate independent of MCE, and reflect in vivo 
stimulation of precursors cells one step prior to preadipocyte commitment. This raises 
the question as to whether or not compounds previously characterized anti-adipogenic 
in 3T3-L1 systems are able to inhibit adipogenesis in models less dependent on MCE 
events. To pursue this question we tested quercetin in 10T1/2 cells, and found that 
quercetin (50µM) significantly inhibited lipid accumulation and that this effect was not 
time dependent (see Appendices 2 and 3). Although further work needs to be done in 
this model system, our preliminary data suggest that quercetin’s effect is not limited to 
the 3T3-L1 model system, affirming that quercetin may inhibit adipogenesis in vivo. 
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 Because AMPK has been implicated to inhibit differentiation and cell cycle 
progression, we investigated whether Compound C, an AMPK inhibitor, mediates 
quercetin’s effect on adipogenesis, testing the hypothesis that quercetin may inhibit 
adipogenesis via AMPK activation. Both strong activation and strong inhibition of 
AMPK has been shown to inhibit adipogenesis suggesting AMPK is tightly regulated 
during these early stages. Compound C inhibits adipogenesis at high concentrations 
(>1μM), therefore lower concentrations were used (0.1-1μM) in combination with 
quercetin (25 and 50μM). Preadipocytes were stimulated to differentiate in the presence 
of both of these compounds. Lipid accumulation was measured at Day 6 (see Appendix 
4). Compound C did not mediate quercetin’s effect at any concentration, suggesting 
that quercetin may inhibit adipogenesis through AMPK-independent pathways. Protein 
analysis confirming Compound C’s ability to block AMPK activation is needed to 
further demonstrate that Compound C is still effective at lower concentrations.  
 The physiological impact of inhibiting cell cycle and thus adipogenesis could be 
viewed positively or negatively: (1) it would be beneficial to mediate the accelerated 
rate of adipogenesis seen in childhood obesity, early stages of obesity, or in patients 
taking TZD drugs used for type 2 diabetes, or (2) it would be harmful to alter the 
body’s natural response to increase fat storage, and potentially accelerate the 
hypertrophy of mature adipocytes leading to their dysfunction. Both views are valid at 
this point because of our limited knowledge of in vivo regulation of adipogenesis, 
however quercetin should not be thought to completely block adipogenesis but rather 
mediate an accelerated, irreversible, over-stimulation of adipogenesis. It is also 
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important to consider quercetin’s effect on mature adipocytes, to gain a holistic view of 
quercetin’s potential as an anti-obesity agent.  
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CHAPTER 3 
EFFECT OF QUERCETIN ON ADIPOCYTE METABOLSIM 
 
3.1 Literature Review 
 
 The rise in obesity will significantly decrease life expectancy and continue to 
burden health care systems because of increased risk for the development of chronic 
disease [95]. Therefore, feasible, large-scale prevention and treatment options must be 
made available to the public in order to reverse this growing epidemic. At the cellular 
level, obesity is defined as the increase in size (hypertrophy) and number (hyperplasia) 
of adipocytes. Hypertrophy of adipocytes leads to their dysfunction as the endoplasmic 
reticulum and mitochondria are unable to keep up with increased metabolic demands. 
Dysfunctional adipocytes become insulin resistant and elicit macrophage induction to 
the adipose tissue further promoting the development of chronic disease [3]. Therefore 
understanding adipocyte metabolism and preventing adipocyte hypertrophy is a critical 
approach in the fight against obesity.  
 Adipocytes handle lipid storage through the synthesis (lipogenesis) and 
breakdown (lipolysis) of triglyceride. Naturally, there is much interest in factors that 
inhibit lipogenesis and promote lipolysis. However, adipocytes are also capable of 
burning stored fatty acids through β-oxidation, providing an exciting approach against 
hypertrophy. AMP-activated protein kinase (AMPK), the major metabolic regulator of 
all cells, has been shown to induce partial lipolysis and β-oxidation [57]. Therefore 
AMPK activators are one such way to metabolically alter adipocytes. 
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 Several bioactive compounds have been identified as AMPK activators [16].  
One such compound is quercetin, the most commonly consumed dietary flavonoid in 
the western diet. Not only has quercetin been implicated as an AMPK activator [13], in 
vivo studies have shown quercetin has the ability to improve hyperglycemia, 
dyslipidemia, and blunt excess weight gain in animal models of obesity and diabetes [7-
10]. However the role of quercetin on adipocyte metabolism remains largely unknown.  
 Several reports have identified quercetin’s effect on mature adipocytes to be 
lipolytic [101, 102], apoptotic [11, 13, 96, 98], and anti-inflammatory [103]. In the 
early 1990s, Kuppusamy et al. carried out experiments with several flavonoids and 
showed that quercetin, among others, inhibited phosphodiesterase break down of cAMP 
and increased lipolysis in the presence or absence of a lipolytic agent [102]. They 
further found that this effect was mediated through activation of β-adrenergic signaling, 
as the effect was inhibited by an β-adrenergic antagonist [101]. Furthermore, Ohkoshi 
et al. [104] found extract from Nelumbonecifera containing quercetin metabolites to 
also stimulate lipolysis in white adipose tissue. Thus, quercetin is generally recognized 
as lipolytic, however the mechanism remains unknown. 
 Currently, no studies have characterized quercetin’s ability to activate β-
oxidation, which is a likely hypothesis given quercetin’s ability to activate AMPK. 
 
3.2 Purpose of Study 
 Quercetin, a widely consumed dietary flavonoid, holds enormous potential as an 
anti-obesity agent. Recently quercetin has been implicated as an AMPK activator, 
bringing into question its ability to induce lipolysis and β-oxidation in adipocytes. We 
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therefore aimed to fill this gap of knowledge by testing quercetin’s effect on lipolysis 
and fatty acid oxidation, specifically through the activation of AMPK. To test this, in 
mature 3T3-L1 adipocytes we investigated (1) quercetin’s action on AMPK and 
downstream target ACC at the protein level, (2) quercetin’s action on free fatty acid 
content in the media, and (3) quercetin’s effect on mRNA expression of PGC-1α, UCP-
1 and UCP-3.   
 We hypothesized that (1) quercetin would increase protein levels of 
phosphorylated AMPK and the downstream target ACC, and that Compound C, an 
AMPK inhibitor, would inhibit this effect, (2) quercetin would increase free fatty acid 
(a lipolytic effect) and that Compound C would block this effect, and (3) quercetin 
would increase mRNA expression of PGC-1α, UCP-1 and UCP-3 (genes involved in 
fatty acid oxidation) and that Compound C would block this effect.   
 
3.3 Materials and Methods 
 
3.3.1 Cell Culture and Treatments 
For the differentiation of 3T3-L1 preadipocytes, cells were grown to 100% confluence 
in Growth Media [DMEM (high glucose), 10% Calf Serum, 1% Penicilin/ 
Streptamycin] replaced every two days. Two days post-confluence, growth media was 
changed to Differentiation Media [DMEM (high glucose), 10% Fetal Bovine Serum, 
1% P/S, 1% Insulin, 1% 3-Isobutyl-1-methylxanthine 11.5mg/ml, 0.01% 
Dexamethasone 3.9mg/ml] in the presence or absence of quercetin aglycone (Sigma-
Aldrich Catalog # 6151-25-3). Three days post-differentiation, media was replaced with 
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Post-Differentiation media [DMEM (high glucose), 10% Fetal Bovine Serum, 1% P/S, 
1% Insulin, +/- quercetin]. 3T3 L1 preadipocytes generally reach 80 -90% 
differentiation 8 to 9 days post MDI induction.  At this point cells were washed with 
PBS to remove residual serum and insulin, and media was replaced with serum and 
insulin free DMEM supplemented with 0.5% bovine serum albumin (BSA) in the 
presence or absence of treatment. (Quercetin : 25, 50 , 100 μM, AICAR:  0.5, 1 mM, 
and Compound C: 10 μM). Treatment lasted 15-48 hrs at which point cells and media 
were harvested for analysis. 
 
3.3.2 Oil Red O Lipid Staining 
Cells were harvested on desired days and underwent Oil Red O Staining to quantify 
lipid accumulation, as it is an indirect determiner of cell differentiation. Cells, grown on 
24-well and 6-well plates, were treated with 10% formaldehyde in PBS for 1 hour, 
washed with 60% isopropanol, and completely dried. Then, cells were stained with 
0.5% Oil Red O solution in 60:40 (v/v) isopropanol: H2O, for 30 minutes at room 
temperature. Finally wells were washed with distilled water and dried. Optical density 
was then measured at 490nm, after eluting with isopropanol, to quantify lipid 
accumulation. 
 
3.3.3 Protein Isolation and Western Blotting 
Cells were harvested at desired times with RIPA Buffer containing protease inhibitor 
(500ul per p-100 dish). Samples were stored at -80° C until protein quantification. 
Samples were thawed on ice, sonicated, and centrifuged. Supernatant, containing whole 
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cell protein, was transferred to a fresh tube for protein quantification using the 
Bicinchoninic Acid (BCA) assay. A BCA standard curve was established using bovine 
serum albumin (BSA) [2mg/ml] protein and measured at 570nm. Sample 
concentrations were then measured against the standard, and prepared with sample 
buffer to allow for 15μg to be loaded to the gel. Samples were run on acrylamide 
(varying percentages) gels via electrophoresis, and then proteins were transferred to a 
PVDF membrane through wet transfer. Upon successful transfer, membranes were 
blocked with 5% non-fat dry milk, and treated with primary and secondary antibodies 
(purchased from Santa Cruz Biological). HRP detection was done through ECL 
solution. Chemiluminescent bands were captured on x-ray and developed.   
 
3.3.4 RNA isolation and Analysis 
Cells washed with phosphate buffer solution were harvested with Trizol Reagant and 
stored at -80° C until mRNA isolation. For isolation, samples were thawed and 
centrifuged with 200µL chloroform.  Supernatant was transferred to a fresh tube and 
centrifuged with isopropanol (1:1) to precipitate RNA. Isopropanol was removed and 
the pellet was washed three times with ethanol by centrifugation. Pellet was 
resuspended in DEPC water and quantified using a spectrophotometer at 260nm.  
8µg of RNA was used along with SuperScript III reagents to make cDNA which was 
stored at -4°C. Polymerase Chain Reaction was performed with the primers for PGC-1α, 
UCP-1, UCP-3, and adiponectin (see Table 2). Samples were run on an agarose gel 
containing Ethidium Bromide and detected using UV light. Band intensity was 
determined using Image J analysis and adjusted to β-actin. 
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3.3.5 Free Fatty Acid and Glycerol Assays 
Media was collected from wells and stored at 4°C. Free Glycerol Assay (K630-100) 
and Free Fatty Acid Quantification Kits (K612-100) were purchased from BIOVISION. 
Product protocols were followed. In brief, reagents were warmed to room temperature, 
standard curves and samples (undiluted) were added to a 96-well plate. Reagent mix 
was added and plates were incubated for the appropriate time. Absorbance was taken at 
570nm.  
3.3.6 Statistical Analysis 
Samples were collected in at least duplicate or triplicate, and differences between the 
means were determined by student T-test analysis. P-values were considered significant 
at <0.05.  
 
3.4 Results 
 
3.4.1 Quercetin phosphorylates ACC, a downstream target of AMPK 
Quercetin has been implicated as an AMPK activator; therefore we tested in our model 
system whether or not quercetin activates AMPK and its downstream target, acetyl-
CoA Carboxylase (ACC). Quercetin treatment (50μM) increased activated AMPK as 
compared to standard MDI treatment over the course of differentiation (Figure 9A). 
Further, quercetin treatment (25-100μM) increased phosphorylated ACC, and this 
effect was blocked by the AMPK inhibitor Compound C (Figure 9B). This confirms 
that we have a working model to study quercetin’s action dependent on AMPK 
activation. 
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3.4.2 Quercetin induces partial lipolysis 
We next looked at quercetin’s ability to induce lipolysis by measuring release of free 
fatty acids in the media of mature adipocytes treated with serum and insulin-free media. 
Our data pooled from 3 separate trials (total n = 7) show that quercetin (100μM) 
significantly increased the release of free fatty acids significantly and Compound C 
(10μM) blocked this effect (Figure 10).  
 
3.4.3 Quercetin induces oxidative pathways  
Because AMPK is known to induce β-oxidation, we looked at quercetin’s ability to 
induce the expression of PGC-1α, a transcriptional regulator of oxidative genes, 
Uncoupling Protein 1 (UCP-1) and Uncoupling Protein 3 (UCP-3), two of the 
uncoupling proteins expressed in the mitochondria of muscle and brown adipose tissue 
to uncouple oxidation from ATP synthesis. Mature adipocytes were treated with 
quercetin (25-100μM) for 24 hours in serum-free insulin-free media. Quercetin 
increased mRNA expression of PGC-1α, and this effect appeared to be attenuated by 
Compound C treatment (Figure 11). Further, quercetin treatment induced mRNA 
expression of UCP-1 and UCP-3 (Figures 12 and 13). Upregulation of UCP-3 by 
quercetin appeared to be attenuated by Compound C treatment. These results suggest 
quercetin is able to induce uncoupled fatty acid oxidation through the activation of 
AMPK.  
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Figure 9. Quercetin increases protein expression of  pAMPK and pACC. 
Protein analysis of pAMPK and downstream target pACC. (A) 3T3-L1 preadipocytes 
were differentiated in the presence or absence of quercetin (50μM) and harvested at 
subsequent time points throughout the course of adipogenesis to determine AMPK 
activation. In the control pAMPK increased at 12 hour but then decreased to a basal 
level from 24 hour to Day 6. Quercetin treatment sustained pAMPK levels through 
the course of adipogenesis.  (B) Mature adipocytes were treated for 48 hours in 
serum-free insulin-free %0.5 BSA DMEM in the presence or absence of Compound 
C (CC) 10 μM, AICAR (A) 1mM, or quercetin (Q) 25-100μM. AICAR treatment 
increased pACC protein levels and CC attenuated this effect. Quercetin treatment 
dose-dependently increased pACC expression and CC also attenuated this effect. 
These results indicate quercetin activates AMPK pathways and CC, and AMPK 
inhibitor successfully blocked AMPK’s downstream action. 
pAMPK ► 
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Figure 10. Quercetin 100μM increases free fatty acid content in media. 
Mature adipocytes were treated with Compound C (CC) 10µM, Aicar (A) 0.5 
and 1mM, and quercetin (Q) 25-100µM for either 24 or 48hrs and media was 
collected and analyzed for free fatty acid content. Data presented here reflects 
pooled data from 3 separate trials each slightly varied by length of treatment or 
AICAR concentration (n=7). AICAR treatment significantly increased FFA 
content in the media while CC attenuated this effect. Likewise quercetin (100 
µM) significantly increased FFA content and CC attenuated this effect 
suggesting quercetin is able to stimulate FFA release through AMPK 
activation.  
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Figure 11. Quercetin up-regulates mRNA expression of PGC-1α. PGC-1α is 
a transcriptional regulator of β-oxidation among other metabolic pathways. 3T3-
L1 mature adipocytes were treated with AICAR (A) 1mM, Compound C (CC) 
10µM, and quercetin (Q) 25-100µM for 24 hours and harvested for mRNA 
analysis by qualitative PCR. AICAR increased PGC-1α expression and CC 
blunted this effect. Quercetin also increased PGC-1α expression and CC 
attenuated this effect. This data suggests quercetin is able to increase PGC1α 
mRNA through an AMPK dependent pathway. 
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Figure 12. Quercetin up-regulated mRNA expression of Uncoupling Protein 1. 
Uncoupling Protein 1 (UCP-1) is the major thermogenic gene expressed 
predominantly in muscle and brown fat. UCP1 uncouples ATP synthesis from 
mitochondrial oxidation. 3T3-L1 mature adipocytes were treated with quercetin (10-
100μM) for 24 hours. Slight UCP-1 expression was induced in the control between 
Day 8 and 9, however quercetin 50μM and 100μM significantly increased UCP-1 
expression. Troglitazone (Tro 10μM), a diabetic drug and PPARγ ligand had no 
effect on UCP-1 expression. 
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Figure 13. Quercetin increased mRNA expression of Uncoupling Protein 3. 
Uncoupling Protein 3 (UCP-3) is part of the group of uncoupling proteins that 
uncouples ATP synthesis from oxidation in the mitochondria and is a 
transcriptional regulator of β-oxidation among other metabolic pathways. 3T3-L1 
mature adipocytes were treated with AICAR (A) 1mM, Compound C (CC) 10µM, 
and quercetin (Q) 25-100µM for 24 hours and harvested for mRNA analysis by 
qualitative PCR. AICAR increased PGC-1α expression and CC blunted this effect. 
Quercetin also increased PGC-1α expression and CC attenuated this effect. This 
data suggests quercetin increases PGC-1α mRNA through an AMPK dependent 
pathway. 
  Con    A     CC  A/CC  Q25  Q50  Q100  Q25 Q50 Q100 
UCP-3 ► 
+ Compound C 
B-actin ► 
UCP-3 mRNA
Treatment
Con Aicar CC A/CC Q25 Q50 Q100 Q25 Q50 Q100
E
xp
re
ss
io
n 
R
el
at
iv
e 
to
 B
-a
ct
in
0
1
+Compound C
56 
3.4 Discussion  
 
 There is great potential in the use of bioactive compounds to alter adipocyte 
metabolism and thus thwart the progression of adipocyte dysfunction and metabolic 
syndrome. Our preliminary findings suggest quercetin is one such compound. 
In our model system we clearly showed quercetin’s ability to activate AMPK, a target 
in the treatment of metabolic syndrome. 
 AMPK is the major metabolic regulator of the cell, regulated by the level of 
AMP/ATP. As AMP levels rise, more AMP binds to the gamma subunit of AMPK 
causing a conformational change protecting AMPK from being dephosphorylated. Thus 
a rise in AMP results in increased phosphorylated AMPK. It has been determined that 
AMPK is activated by low glucose, hypoxia, ischemia, adiponectin, leptin, and alpha 
adrenergic receptor. It would be of interest to further investigate the mechanism by 
which quercetin activates AMPK. It is possible that quercetin creates a hypoxic 
environment because of its antioxidant capacity. However, it has also been suggested 
that quercetin activates adrenergic receptors to mediate lipolysis, thus it is plausible that 
quercetin may interact with membrane bound receptors [101]. It has been also been 
shown that quercetin is able to penetrates the membrane through passive diffusion and 
significantly accumulates in the mitochondria [105]. In fact, Gledhill et al. determined 
that quercetin binds and inhibits the rotary mechanism of the F1-ATPase, required for 
ATP synthesis in the mitochondria [106].   This action may suggest quercetin activates 
AMPK by lowering the ATP/AMPK ratio in the cell; however, this mechanism would 
need to be further tested. 
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 AMPK has been implicated to induce partial lipolysis and β-oxidation. We 
therefore investigated quercetin’s effect on both of these pathways.  As shown, 
quercetin stimulated free fatty acid release into the media, and this effect was blunted 
by the AMPK inhibitor, Compound C. Figure 10 consists of pooled data from 3 
separate trials, each with a slightly different experimental design. Therefore these trials 
should be repeated with a consistent design. From our experience, the best design 
would be to treat mature adipocytes (80% differentiated) in serum-free, insulin-free 
DMEM supplemented with 0.5% Bovine Serum Albumin (BSA) for 48hrs using 
AICAR (1mM) and Compound C (10μM) concentrations.  
  Interestingly, quercetin significantly reduced glycerol release in the media, and 
Compound C did not consistently reverse this effect in all treatments (see Appendix 5). 
This finding suggests quercetin induces partial lipolysis (the release of free fatty acids 
but not glycerol), and this effect may be through AMPK-independent pathways, as 
AICAR treatment not alter glycerol release. It has been implicated that AMPK 
deactivates HSL the major lipolytic enzyme, however ATGL is still available in the 
cytoplasm to begin TG breakdown by releasing the first free fatty acid (FFA) [52]. 
Therefore, if HSL is inactivated by AMPK incomplete lipolysis occurs, which explains 
why free fatty acid is released but not glycerol. However, this explanation does not 
account for the significant decrease in glycerol release seen with quercetin treatment; 
therefore quercetin may act independently of AMPK on glycerol metabolism.  It would 
be of great interest to explore the mechanism behind this observation, specifically by 
looking at the activity of glycerol-3-phosphate dehydrogenase in the mitochondria, and 
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aquaporin 3 and 9, which are membrane bound glycerol transporters, all of which 
regulate glycerol release during lipolysis. 
 Quercetin increased PGC-1α, UCP-1 and UCP-3 mRNA expression, suggesting 
quercetin induces uncoupled oxidation in the cell. These preliminary findings should be 
repeated, as results here only reflect one trial and qualitative RT-PCR is not as precise 
as real-time PCR analysis. Interestingly, it appears that Compound C blunted 
quercetin’s ability to induce PGC-1α, and UCP-3, suggesting that  AMPK activation 
may be the mechanism by which quercetin induces oxidation. Quercetin’s effect on 
UCP-1 expression in the presence of Compound C was not investigated here and is 
worth exploring. Other researchers found that chronic AMPK stimulation through 
AICAR induced mitochondrial biogenesis and fatty acid oxidation , but did not 
stimulate UCP-1 expression [48, 107].Therefore it is likely that quercetin may stimulate 
UCP-1 through an AMPK-independent pathway. These exciting preliminary findings 
showing quercetin ability to stimulate uncoupled β-oxidation would have far reaching 
effects if translated into human cells lines and further into in vivo models. Potentially 
quercetin could enhance β-oxidation in hypertrophied adipocytes enabling them to 
prevent or recover from metabolic dysfunction, from the burden of excess lipid.  
 Although mRNA expression seen in this research suggests quercetin induces 
uncoupled fatty acid oxidation, further research needs to be done to confirm this effect. 
In particular it would be of interest to determine whether or not quercetin increases 
oxygen consumption, which would be an indication of increased mitochondrial function. 
Quercetin did not significantly decrease triglyceride content in mature adipocytes over 
a 48hr period in our model system (see Appendix 6).  In animal studies, quercetin doses 
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did result in weight loss [7] suggesting prolonged treatment of quercetin might be 
necessary to see dramatic changes in adipocyte lipid content. Increased uncoupled 
oxidation of free fatty acids in adipose tissue provides a possible mechanism for 
quercetin’s effect.  
 Quercetin’s ability to stimulate partial lipolysis and uncoupled fatty acid 
oxidation in vivo could potentially prevent and/or alleviate the progression of 
hypertrophied adipocytes. It is carefully noted that releasing free fatty acids into 
circulation is not ideal given cardiovascular risk; however partial lipolysis would evoke 
a mild effect in vivo, because essentially only a small fraction of the broken down 
triglyceride would be released. The remaining diglyceride would be further metabolized 
in the cell, likely through uncoupled β-oxidation. Therefore, these findings suggest that 
quercetin may improve signs of metabolic syndrome, specifically hyperglycemia and 
insulin sensitivity, in vivo by preventing or ameliorating the lipid burden in 
hypertrophied adipocyte through AMPK mediated metabolic changes.  
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CHAPTER 4 
CONCLUSION & FUTURE DIRECTIONS 
 
4.1 Summary 
 
 Obesity is one of the most pressing concerns of health care officials because of 
its increasing prevalence and significant link to the development of type 2 diabetes, 
cardiovascular disease and cancer. At the cellular level obesity is defined as the 
increase in cell number (hyperplasia) and cell size (hypertrophy), resulting in the 
irreversible expansion of adipose tissue in unwanted depots and the dysfunction of 
adipocytes leading to the development of metabolic system. Our findings here 
demonstrate that quercetin, the most widely consumed dietary flavonoid, shows 
promising potential as an anti-obesity agent because of its ability to target both 
hyperplasia and hypertrophy in our in vitro model.  
 We found that quercetin inhibited adipogenesis in 3T3-L1 preadipocytes 
through altering cell cycle events, specifically cell number, and expression of cell cycle 
regulators Cyclin A and p27. These findings are significant as in vivo hyperplasia has 
been implicated to be tightly controlled by cell cycle [35]. In 10T1/2 mesenchymal 
stem cells, a cell line one step removed from preadipocyte commitment, quercetin 
significantly inhibited adipogenesis, further supporting quercetin’s potential as an anti-
adipogenic agent in vivo. Quercetin has been implicated as an AMPK activator [13], 
and further either strong inhibition or activation of AMPK inhibits adipogenesis 
through MCE events. However our preliminary findings did not indicate that 
quercetin’s anti-adipogenic effect is AMPK dependent. 
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 In mature adipocytes, quercetin induced lipolytic and oxidative pathways. 
Quercetin significantly increased free fatty acid content in the media, and up-regulated 
expression of PGC-1α, Uncoupling Protein 1 (UCP-1) and 3 (UCP-3). Compound C, 
an AMPK inhibitor, blunted these effects suggesting quercetin’s action is AMPK 
dependent. These initial findings indicate quercetin may be able to shift adipocytes 
toward energy burning pathways, which could alleviate adipocyte hypertrophy 
in vivo. 
 
4.2 Limitations   
 
There are a few limitations of the work presented here that are important to 
discuss. First is the concentration of quercetin used in our in vitro model. Physiological 
levels generally approach the 200nM range, however the concentration used in our 
experiments were 25, 50, and 100µM. These in vitro levels have never been reached in 
humans, and would likely only result from enhanced supplementation such as 
nanoparticle delivery of quercetin. Nonetheless, in vitro studies allow researchers to 
understand mechanistic aspects of quercetin’s action.  
A second limitation we encountered was the use of Compound C to investigate 
whether quercetin’s anti-adipogenic effect was AMPK dependent. Compound C at high 
doses (5-10µM) inhibited adipogenesis (data not included), therefore lower 
concentrations (0.1-1µM) were used in combination with quercetin. However, this 
brings into consideration Compound C’s effectiveness to inhibit AMPK at such a low 
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dose. Therefore, other strategies for determining whether quercetin anti-adipogenic 
effect is through AMPK activation need to be developed.  
 A third limitation was sample size, due to time constraints. Most of the work 
presented here is in the preliminary stage and needs to be repeated in order to gain 
statistical significance. However we were able to gain valuable insight from these initial 
findings. 
 Finally a major limitation not encountered here but commonly encountered with 
human supplementation trials of quercetin is bioavailability. To date, human studies 
have only shown quercetin supplementation to reduce systolic blood pressure [91]. 
Quercetin has been shown to be safe at high doses [108] therefore pharmacological 
doses can be used. However absorption is still variable from individual to individual 
because of the gut microflora’s ability to metabolize quercetin. One possible way to 
overcome this limitation is through the use of nanoparticle quercetin delivery, which is 
currently being developed [73, 109]. 
 
4.3 Significance of findings in the context of obesity and metabolic syndrome 
 
 In vivo animal studies have shown quercetin to ameliorate metabolic syndrome, 
specifically insulin resistance, hyperglycemia, and weight gain. Our findings here of 
quercetin’s effect on adipocytes help speculate on the mechanisms behind quercetin’s 
in vivo effects.  
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4.3.1 Weight Management 
 Quercetin’s ability to stimulate oxidative pathways, specifically thermogenesis, 
through AMPK activation is an exciting new finding that suggests quercetin may be 
able to attenuate weight gain and help promote weight loss in obese individuals. 
Currently a major focus of anti-obesity drug designers is targeting thermogenesis to 
increase resting metabolic rate [110]. It is known that those with lower daily energy 
expenditure are more susceptible to obesity  [111]. As an individual’s body mass 
increases, their resting metabolic rate will increase to maintain the excess tissue, 
however it has been shown that after weight loss, post-obese individuals have a reduced 
metabolic rate [112]. Further fatty acid oxidation is impaired in obese individuals, even 
after weight loss [110, 113]. The only uncoupling drug used in humans, dinitrophenol, 
resulted in weight loss up to 3kg per week, but caused sweating and worse hypoxia 
[114]. Therefore milder thermogenic agents are currently being pursued to obtain 
similar weighty loss effects at a safer level.  
 Quercetin’s ability to increase metabolic rate has been determined in animals 
but not yet in humans. Stewart et al. [115] looked at energy expenditure, as measured 
by indirect calorimetry, in C57BL/6J mice fed a high-fat diet with quercetin (0.8g/kg) 
for 8 weeks. At week 3, energy expenditure was significantly higher (p<0.05) in the 
quercetin group over the control, however at week 8 there was no difference observed 
between the two groups.  Based on this finding in animals, and quercetin’s proposed 
ability to stimulate oxygen consumption in muscle cells [116], Egert et al. conducted a 
pilot study in humans to test quercetin’s ability to increase metabolic rate. Six healthy 
normal-weight women were given 150mg doses of quercetin and respiratory 
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consumption of oxygen was measured 5 min – 3 hours post-ingestion, however no 
significant difference was found with quercetin treatment. This result is likely due to 
the small sample size (n=6) and lower dosage of quercetin (300 times lower than 
Stewart et al. dosage in rats), therefore plasma quercetin concentrations may have been 
below the threshold for any observed metabolic effect. Our findings that quercetin 
increases mRNA expression of UCP-1, UCP-3 and PGC-1α in 3T3-L1 adipocytes 
strongly supports continued efforts to determine quercetin’s metabolic effects in vivo.  
 
4.3.2 Insulin Sensitivity  
 Quercetin has repeatedly been shown to improve hyperglycemia and insulin 
sensitivity in animal models. Our findings that quercetin stimulates AMPK, induces β-
oxidation, and increases adiponectin mRNA expression all suggest potential 
mechanisms for quercetin’s in vivo effect. AMPK is a major target for drug companies 
AMPK has been shown to improve glucose uptake in vitro and improve hyperglycemia 
in vivo. Furthermore, the commonly prescribed class of diabetic drugs, 
Thiazolidinediones (TZDs), have been shown to activate AMPK [117]. Chronic use of 
these drugs has been associated with negative side-effects therefore milder activators of 
AMPK are wanted to allow for long-term use [66, 118].  We clearly showed quercetin’s 
ability to activate AMPK in 3T3-L1 preadipocytes. Therefore, quercetin holds great 
potential as an anti-diabetic agent, and AMPK activation is likely the mechanism 
behind quercetin’s in vivo effect. So far quercetin has been shown to improve glucose 
uptake in adipocytes [119] and in muscle cells [120], and AMPK has been implicated in 
the mechanism. 
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 One area that warrants future research is quercetin’s ability to increase 
adiponectin levels and the anti-diabetic effects associated with that. Adiponectin levels 
are negatively correlated with obesity and type 2 diabetes [121], and further 
administration of adiponectin in rats improves glucose regulation [122]. Quercetin 
treatment has been shown to increase circulating adiponectin levels in animal models [7, 
8, 123]. To our knowledge no human studies have explored quercetin’s ability to 
increase circulating adiponectin levels and our preliminary findings that show 
quercetin’s ability to increases mRNA expression of adiponectin in mature adipocytes 
certainly warrant this exploration. 
 
4.4 Application of Quercetin from a Public Health Perspective 
 
 Estimating quercetin content in plants is extremely limited due to the variability 
in flavonoid production based on environmental as well as genetic factors [65], 
therefore limited data exists on the correlation between quercetin intake and chronic 
disease. Because of this missing link, it is too soon for public health officials to develop 
feasible recommendations to the public for the use of quercetin as an anti-obesity agent.  
 Our working knowledge, based largely on supplementation studies done by 
Egert et al., is that 150mg supplemental doses (roughly the equivalent of 12-15 servings 
of fruits and vegetables) may not be sufficient to elicit the powerful health benefits 
found in animal models using nearly 200 to 300 times the dosage amount. Therefore it 
can be speculated that the future use of quercetin as an anti-obesity agent will be 
66 
through supplementation or product enhancement, from which a quercetin intake of 
around 1000mg could be reached.   
 This gap in our current knowledge should not however detract from the 
recommendation of health officials to increase consumption of quercetin through intake 
of fruits and vegetables, specifically those high in quercetin (onions, apples, kale, etc.). 
It is likely that sustained lower doses (50-100mg, the equivalent of roughly 5-8 servings 
of fruits and vegetables) would have a preventative effect, while higher doses would be 
required to use quercetin therapeutically to treat conditions related to obesity.  
 
4.5 Direction of Future Research 
 
4.5.1 Quercetin’s effect on adipogenesis 
 Although our findings here suggest quercetin inhibits adipogenesis through 
altering cell cycle events, this effect should be further confirmed in vitro through the 
use of (1) a more accurate cell counting technique, NucleoCounter, (2) Flow Cytometry, 
to quantify the number of cells in each cell cycle stage, and (3) human cell lines that 
may behave differently than 3T3-L1 preadipocyte because of pluripotency stage. Once 
quercetin’s effect has been confirmed in vitro, animal studies should be employed in 
order to determine quercetin’s ability to inhibit hyperplasia in various adipose depots. 
 
4.5.2 Quercetin’s effect on mature adipocytes 
 
 Our preliminary findings suggest quercetin may induce partial lipolysis and 
shift the cell toward uncoupled β-oxidation. To further confirm this effect in vitro (1) 
our experiments should be repeated at least two times to gain validity, and (2) oxygen 
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consumption should be analyzed to determine quercetin’s ability to increase 
mitochondrial oxidation. Next it would be of interest to determine whether quercetin 
decreases adipocyte size in an obese animal model. This would confirm quercetin’s 
ability to ameliorate hypertrophied cells and the consequences associated with them. It 
should also be determined whether quercetin improves adiponectin levels in vivo as our 
findings indicate quercetin increases mRNA expression of adiponectin.  
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APPENDIX 1 
QUERCETIN MAY INHIBIT NOX4 EXPRESSION DURING THE EARLY 
STAGES OF ADIPOGENESIS 
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Appendix 1. NADPH oxidase 4 (NOX4) is a major producer of reactive oxygen 
species (ROS) in the cell. During mitotic clonal expansion NOX4 has shown to be 
required for ROS signaling that promotes cell cycle events. Here we investigated 
whether quercetin treatment alters NOX4 mRNA expression. Our hypothesis was 
that quercetin would inhibit or alter NOX4 expression, thus inhibiting mitotic 
clonal expansion (MCE), a process required for terminal differentiation. 3T3-L1 
preadipocytes were differentiated in the presence or absence of quercetin (50µM) 
and harvested at subsequent time points (0,6,12,24,36,48 hours) for mRNA 
analysis to characterize NOX4 mRNA expression during MCE. In the absence of 
quercetin Nox 4 expression rose steadily from 6 hours to 36 hours and then was 
down-regulated by 48 hours. However in the presence of quercetin NOX4 mRNA 
expression was completely blunted until slight stimulation came on a 36 and 48 
hours. Similar to Cyclin A  (see Figure 9) results, it is possible that quercetin’s 
anti-oxidant capacity is responsible for blunting the expression of NOX4 and that 
by 36 hours quercetin’s anti-oxidant capacity is quenched, allowing the cells to 
signal a delayed response to the adipogenic cocktail (MDI). The implications of 
these findings would be that quercetin may inhibit cell cycle progression by 
blunting the signaling pathways involved in initiating and sustaining cell cycle 
events. It has also been shown that strong antioxidant treatment inhibit cell cycle, 
therefore the mechanism by which quercetin inhibits cell cycle is likely through 
it’s anti-oxidant capacity. It would be of interest to determine ROS levels during 
early time points to confirm quercetin ability to quench ROS. 
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Appendix 2. 10T1/2 mesenchymal stem cells are an adipogenic cell line model one-
step removed from preadipocytes commitment, they therefore more closely model 
adipogenesis as it occurs from the initial recruitment of stromal vascular stem cells 
to preadipocytes to mature adipocytes. This cell line has been determined to be less 
reliant on mitotic clonal expansion (MCE) for terminal differentiation therefore it 
was of interest to test quercetin’s effect on their differentiation. Our hypothesis was 
that if quercetin inhibits adipogenesis through MCE events then quercetin would 
have no effect on 10T1/2 cell differentiation. 10T1/2 cells were differentiated in the 
presence or absence of quercetin (1, 5, 10, 20, 50µM) and harvested at Day 8 to 
measure lipid accumulation, an indirect measure of adipogenesis, by Oil Red O 
staining. Quercetin (50µM) significantly inhibited lipid accumulation by Day 8, 
indicating that quercetin is able to inhibit adipogenesis in adipogenic models less 
depending on MCE, further affirming quercetin potential to inhibit adipogenesis in 
vivo. It should be noted that lower concentrations of quercetin did not significantly 
inhibit lipid accumulation. 10T1/2 cells are thought to be more sensitive than 3T3-
L1 preadipocytes to treatments, therefore the fact that lower concentrations had no 
effect may suggest that quercetin’s effect in 10T1/2 cells is indeed weaker and only 
very strong doses has an effect.  
 
APPENDIX 2 
QUERCETIN INHIBITS LIPID ACCUMULATION OF 10T1/2 
MESENCHYMAL STEM CELLS 
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APPENDIX 3 
QUERCETIN’S INHIBITORY EFFECT IS NOT LIMITED TO EARLY TIME 
POINTS IN 10T1/2 MESENCHYMAL STEM CELLS 
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Appendix 3. Our results indicate that quercetin’s inhibitory effect in 3T3-L1 
preadipocytes is limited to the first 36 hours of differentiation, when mitotic clonal 
expansion (MCE) is occurring. 10T1/2 mesenchymal stem cells model an 
uncommitted model vascular stromal stem cell differentiation, and have been 
determined to be less dependent on MCE events for terminal differentiation.  
Previous findings indicate quercetin (50µM) inhibits lipid accumulation (appendix 
2), therefore we hypothesized that if quercetin is able to inhibit adipogenesis in 
10T1/2 cells independent of MCE, quercetin’s effect will not be time-dependent. 
10T1/2 cells were differentiated at time 0 hour and quercetin (50µM) was added to 
differentiating media at subsequent times (0, 6, 12, 24 and 48 hours) and continued 
until Day 8, when all cells were harvested for Oil Red O staining to determine 
lipid accumulation. Quercetin treatment consistently inhibited lipid accumulation 
regardless of treatment time. Interpretation of this data is difficult because of our 
limited understanding of mitotic clonal expansion events in 10T1/2 cells. It is 
possible that MCE events last longer in 10T1/2 cells therefore it would be of 
interest to test the effect of quercetin treatment given past 48 hours to see if at 
some time point quercetin has no effect. It is also important to characterize 
quercetin’s effect on adipogenic factors (PPAR γ, C/EBP α, aP2 and ACC).  
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APPENDIX 4 
COMPOUND C DID NOT REVERSE THE ANTI-LIPOGENIC EFFECT OF 
QUERCETIN 
   
Appendix 4. AMP-activated protein kinase (AMPK), the major metabolic regulator of 
the cell, has been demonstrated to control mitotic clonal expansion (MCE) in 3T3-L1 
preadipocytes, as either inhibition or activation inhibits MCE and differentiation. Our 
preliminary findings demonstrate quercetin activates AMPK during MCE events and 
throughout the course of differentiation (see Figure 8A), therefore we hypothesized that 
the AMPK inhibitor, Compound C, will attenuate quercetin’s anti-adipogenic effect by 
counteracting quercetin’s activation of AMPK. 3T3-L1 preadipocytes were 
differentiated in the presence or absence of quercetin (Q) 25-50µM and Compound C 
(CC) 0.1-1µM and harvested at Day 6 for Oil Red O staining to measure lipid 
accumulation (n=4). As expected, quercetin treatment alone inhibited lipid 
accumulation. CC treatment slightly inhibited lipid accumulation; however this 
inhibition was not detectable by microscope observation. CC, at any concentration, did 
not improve lipid accumulation in the presence of quercetin. These preliminary results 
suggest quercetin inhibits adipogenesis independent of AMPK pathways. To confirm 
this hypothesis, pAMPK protein levels should be determined throughout the course of 
adipogenesis to determine whether CC at low doses (0.1-1µM) effectively inhibited 
AMPK activation. CC at higher doses (5 -10µM) inhibited lipid accumulation 
comparable to quercetin 50µM treatment (data not shown); therefore lower 
concentrations were selected for this experiment to avoid a confounding effect.  
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APPENDIX 5 
QUERCETIN TREATMENT IN MATURE ADIPOCYTES RESULTS IN 
DECREASED GLYCEROL CONTENT IN THE MEDIA 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5. Lipolysis is the breakdown of triglyceride into free fatty acids and glycerol, 
which are released from the cell. Researchers have previously determined quercetin 
enhances lipolysis however the mechanism remains unknown. Our findings and others 
indicate quercetin activates AMP-activated protein kinase (AMPK), the major metabolic 
regulator of the cell. AMPK has been implicated to induce partial lipolysis, the release 
of free fatty acid, but not glycerol. We therefore tested quercetin’s effect on glycerol 
release in the presence or absence of an AMPK inhibitor, Compound C (CC) to 
determine whether quercetin’s effect on glycerol release was dependent on AMPK 
activation. Our hypothesis was two fold (1) if quercetin induces lipolysis, then quercetin 
treatment will increase glycerol release independent of CC treatment, and (2) if 
quercetin induces partial lipolysis, as seen with AMPK activation, then quercetin 
treatment will not alter glycerol release. Mature adipocytes were treated with AICAR 
(0.5-1mM), CC (10 µM) and quercetin (Q) (25-100µM) for 15-48hrs in serum free, 
insulin free media. Media was collected and analyzed for glycerol content. Data from 3 
trials (n=7) was pooled and shown here. Each trial had a slightly different experiment 
design, either varied by AICAR treatment (0.5 or 1mM) or length of treatment time (15, 
24, or 48 hours). The pooled data showed quercetin treatment significantly decreased 
glycerol content in the media, indicating quercetin’s effect is neither lipolytic nor 
partially lipolytic through AMPK activation. Interestingly CC only blunted the effect of 
the strong quercetin treatment (100µM). These findings suggest quercetin treatment 
alters the normal metabolism of glycerol, and therefore future studies should look at 
quercetin’s effect on glycerol metabolism, specifically glycerol-3 phosphate 
dehydrogenase (GPDH) in the mitochondria. Insight here will illuminate quercetin’s 
overall metabolic effect on mature adipocytes.  
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APPENDIX 6 
QUERCETIN TREATMENT IN MATURE ADIPOCYTES FOR 48 HOURS DID 
NOT ALTER INTRACELLULAR TRIGLYCERIDE LEVELS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 6. Adipocytes undergo lipolysis to breakdown stored triglyceride for use 
in the body. Quercetin has been implicated to stimulate lipolysis.  Further 
quercetin has also been implicated to activate AMPK, which is known to stimulate 
partial lipolysis. We therefore tested whether quercetin treatment significantly 
reduced the amount of store triglyceride content and whether the AMPK inhibitor, 
Compound C mediated this effect. Mature adipocytes were treated with Compound 
C (CC) 10µM, Aicar (A) 0.5 and 1mM, and quercetin (Q) 25-100µM for either 24 
or 48hrs and media was collected and analyzed for free fatty acid content. Data 
presented here reflects 1 trial (n=3). No treatment significantly altered triglyceride 
content in the cell. This is likely because any quantifiable change in triglyceride 
content would take a longer treatment period, since mature adipocytes are resistant 
to purging lipid.  
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APPENDIX 7 
QUERCETIN UPREGULATES MRNA EXPRESSION OF ADIPONECTIN 
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Appendix 7. Adiponectin, an adipokine known to improve insulin sensitivity, is 
negatively associated with obesity. Therefore increasing adiponectin levels in 
obese individuals may be beneficial. Mature adipocytes were treated with 
AICAR (A) 1mM, Compound C (CC) 10µM, and quercetin (Q) 25-100µM for 
24 hours and harvested for mRNA analysis by qualitative PCR. AICAR and CC 
treatment equally stimulated adiponectin mRNA expression, however quercetin 
treatment dramatically up-regulated expression. CC attenuated this effect 
suggesting quercetin may increase adiponectin mRNA expression through an 
AMPK dependent mechanism.    
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